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ABSTRACT 
 
 
ACUTE PHARMACOLOGICAL TREATMENT GIVEN TO OLDER ADULTS WITH 
ACUTE MYOCARDIAL INFARCTION: A NATIONWIDE EMERGENCY DEPARTMENT 
STUDY, 1992–2010 
Maryam S. Alowayesh, MSc 
Virginia Commonwealth University, 2013 
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of 
Philosophy at Virginia Commonwealth University 
Spencer E. Harpe, PharmD, MPH, PhD 
Associate Professor 
Department of Pharmacotherapy and Outcomes Science 
 
OBJECTIVE: To determine the pattern and predictors of use of antiplatelet agents and beta-
blockers given in the emergency department (ED) to older adults with acute myocardial 
infarction (AMI) and its effects on in-hospital mortality and length of hospital stay (LOS) and to 
determine the effect of computerized ED guideline reminders on their utilization. 
METHODS: A cross-sectional study using the National Hospital Ambulatory Medical Care 
Survey (NHAMCS) ED data for years 1992 to 2010 was conducted. Patients were included if 
they had an admission diagnosis of AMI (ICD-9-CM code 410.xx) and were ≥55 years. Survey 
logistic regression was used to examine whether there was a trend in the use of antiplatelet 
agents and beta-blockers across the years and to explore the association between various 
predictor variables and their utilization rates. The chi-square test was used to see whether users 
of these drugs were different from non-users in their rates of in-hospital mortality. Survey linear 
regression was used to explore the effect of utilization of these drugs on LOS. All the visits were 
xi 
 
weighted to get national estimates. All of the analyses were carried out with SAS 9.3 statistical 
package.
 
RESULT: A total of 1,771 visits (weighted frequency = 6.1 million) by patients were selected 
for this study. Both anti-platelet agents and beta-blockers were shown to have a positive trend 
across the years. Age, sex, chest pain, triage, using an ambulance, and metropolitan region were 
all found to be significant predictors of either antiplatelet agent or beta-blocker utilization. Use 
of beta-blockers was associated with lower in-hospital mortality. Neither drug class had an effect 
on LOS. Finally, patients who were treated in EDs with computerized guideline reminders were 
twice as likely to get an antiplatelet agent, but this was not seen with beta-blockers. 
 
CONCLUSION: This study displayed a positive pattern across the years in the use of 
antiplatelet agents and beta-blockers given to older AMI patients. It also showed that age, sex, 
and other important variables were significant predictors of their utilization. The use of beta-
blockers yielded lower in-hospital mortality. Finally, the use of ED reminders increased 
antiplatelet agent utilization. 
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CHAPTER 1 
 
Introduction 
 
Acute Myocardial Infarction Statistics 
Heart disease is the number one cause of death in the United States; accounting for 
617,000 deaths in 2008.
1
 Almost 1.2 million older adults, defined as those adults aged 65 years 
and older, were discharged from a hospital with heart disease in 2008-2009. Approximately half 
of those were discharged with acute myocardial infarction (AMI).
2-3
 Older adults represent about 
13% of the US population, yet account for 60% of hospital discharges for AMI and almost 90% 
of AMI in-hospital deaths.
3-4 
Cardiovascular morbidity and mortality rates rise even more rapidly 
in patients 75 years or older.
5
  
Despite the high prevalence of AMI morbidity and mortality in the older adult 
population, limited randomized clinical trial data is available to guide their care.
5 
Although 
explicit age-based exclusions in clinical trials have become less frequent since 1990, age-based 
exclusions still appear.
6-8
 Even when age-based exclusions are eliminated from these clinical 
trials, implicit age-based exclusions are still a concern.
9
 For example, physician/investigator 
preference or the types of sites involved in the recruitment process may create implicit exclusion 
criteria that affect the type of patients enrolled, which may in turn affect the generalizability of 
the findings.
9 
AMI Treatment Timeliness 
AMI treatment is a timely matter, so delay in evidence-based acute therapies may put 
patients at risk.
10
 Hence, there is emphasis in the literature on the importance of initiating AMI 
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treatment in the emergency department (ED).
11-12
 The ED is considered to be a critical setting for 
measuring AMI care since therapies started in the ED are more likely to be continued during 
hospitalization with a lasting impact on patient outcomes.
11-12
 The Institute of Medicine has 
identified the ED as the part of the health care system in most need of improvement.
13
 The ED 
faces a lot of challenges like boarding of admitted patients in the ED, crowding, and ambulance 
diversion. AMI is considered an ideal disease for studying ED quality of care since it is initially 
treated in the ED and its therapies are time-sensitive and may impact mortality.
12,14
 Despite its 
importance, quite few resources have been directed at studying AMI care in the ED.
12 
AMI management in the ED is related to the “3 T’s”—triage, treatment, and timeliness of 
specialty consultation.
10 
Initial triage effectiveness governs patient outcomes because empiric 
therapy often will be started (e.g. aspirin) and patients will be risk stratified.
 
It is challenging to 
triage patients in the ED, as it has to be done in a short time period with limited information.
10 
Triaging older patients is even more challenging since they frequently present with atypical 
symptoms like no chest pain, dizziness, and shortness of breath, often called a silent MI.
15
 
Receiving care by a multidisciplinary specialist team in the ED (i.e. primary care physician, 
emergency medicine physician, cardiologist, and an ED nurse) is considered to be a class Ib 
recommendation in the American Heart Association (AHA) guidelines; however, it is not always 
feasible.
16
 In this same recommendation, it is also suggested to have written protocols for 
triaging and managing AMI patients in the ED.
16 
Part of these protocols provide the content of 
the admitting orders and must indicate that aspirin and a beta-blocker were given in the ED, and 
if not, what was the reason.
16 
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AMI Guidelines 
A large body of evidence supports the early treatment of AMI with antiplatelet agents and 
beta-blockers.
17-23
Treatment with early administration of beta-blockers is becoming more 
controversial, specifically intravenous (IV) beta-blockers.
24-26 
It has been shown that the early IV 
administration of a beta-blocker to patients who are hemodynamically unstable or show signs of 
heart failure may cause cardiogenic shock.
26
 The early administration of an oral beta-blocker is 
still considered safe and recommended.
20,24
 In this case, practice guidelines are considered to be 
the best tool to guide health professionals’ decisions on AMI treatment by utilizing the strongest 
body of evidence from randomized clinical trials (RCTs) and large observational studies.  
The American College of Cardiology and the American Heart Association (ACC/AHA) 
have used a joint committee since 1980 to guide AMI treatment and other cardiovascular 
diseases.
27 
Approximately every two years they publish a new guideline or update one of the 
existing guidelines.
27-34
 Since 2006, they started publishing performance measures for AMI 
treatment. An update of these measures was published in 2008.
35-36 
 These performance measures 
aim to assist in the measurement of AMI care quality and increase the uptake of AMI 
guidelines.
35
 In the 2006 performance measures, beta-blockers were recommended to be given 
upon ED arrival; however, this recommendation was omitted from the 2008 update.
36
 They argue 
that since there is a distinction between IV beta-blockers and oral beta-blockers and there is a list 
of patient factors that need to be checked before administering a beta-blocker, early beta-
blockers were not fit to be a performance measure because of the complexity of its 
implementation.
36 
4 
 
AMI Initiatives   
 AMI is one of the most extensively studied medical condition in the literature.
37
 In the 
last two decades, AMI mortality decreased by 33%, which is believed to be the result of 
improved AMI treatment.
38 
Numerous quality improvement (QI) initiatives and AMI registries 
contributed to this improvement by enabling the provision of consistent care and the quick 
adoption of clinical advances.
38 
These initiatives aided in the constant measurement of AMI 
quality of care by creating continuous opportunities for improvement.
38
 One of the most well-
known AMI registries is the Global Registry of Acute Coronary Events (GRACE). It is a 
prospective observational project aimed to improve the acute and long-term care in AMI. Patient 
data has been collected in 14 countries since 1999.
39
 
There are many US-based QI initiatives and AMI registries. A well-known governmental 
QI initiative is the Cooperative Cardiovascular Project (CCP). It was initiated in 1992 by the 
Health Care Financing Administration (HCFA, now the Centers for Medicare and Medicaid 
Services) to benefit Medicare patients.
40 
 It is a nationwide program that aims to improve quality 
of AMI care received by Medicare beneficiaries.
40 
The American College of Cardiology (ACC) 
has developed a program called Guidelines Applied in Practice (GAP) with a goal of facilitating 
the use of the ACC/AHA guidelines in practice.
41
 The American Heart Association (AHA) has a 
similar initiative to GAP called the Get With the Guidelines (GWTG) initiative. The ACC and 
the AHA share the same goals in their QI initiatives.
38 
The National Cardiovascular Data 
Registry (NCDR) had the initiative in year 2007 to merge two large AMI registries into one large 
national AMI registry.
38
 The National Registry of Myocardial Infarction (NRMI) and “Can 
Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes with Early 
Implementation of the ACC/AHA Guidelines” (CRUSADE) QI initiative merged into one 
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registry called the Acute Coronary Treatment and Intervention Outcomes Network (ACTION).
38
 
Afterwards, the NCDR still perceived a need for a more unified registry; hence, it facilitated a 
merger in 2008 between the ACTION registry and the GWTG initiative to create the ACTION 
Registry-GWTG (AR-G).
38 
Conceptual Framework 
When studying the quality of care in a certain disease (e.g. AMI), it is best to use a 
framework that has been developed to measure and assess clinical practice. The most utilized 
and widely accepted framework in this area is the Donabedian model, or the structure-process-
outcome model, a simple and persuasive model that combines all aspects of health care.
42
 
To best understand and use the Donabedian model, it is important to explain this triad 
“structure-process-outcome” in more detail. Structure in this model represents material 
resources, human resources, and organizational characteristics, such as the presence of teaching 
and research functions and integrated computer systems. Process, on the other hand, constitutes 
all the activities performed in patient health care, like diagnosis, treatment, and prevention. 
Outcome is the end result of a health care service or activity and reflects any desirable or 
undesirable change in the patient. Outcomes may include clinical, economic, and humanistic 
outcomes.
42
 
There are certain rules or conditions that govern how we use this model. It is important to 
know that structure, process, and outcome are not considered aspects of quality. We can only 
infer that quality is good or bad by the information available to us. Another pivotal rule is that 
without a predetermined relationship between the structure, process, and outcome, no inferences 
can be made. This relationship should be supported by well-established evidence. The stronger 
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this relationship is the stronger the inferences being made. Finally, this model is developed to 
assess clinical practice, so it may not work as well in other settings.
42
 
Choosing the right outcome to assess clinical care is a pivotal step. Donabedian provided 
some guidelines to follow when choosing the outcome. The outcome must be relevant, 
achievable by good care, attributed to health care, and available to collect.
42
 Also, it is important 
to consider the magnitude and duration of the outcome, and when tracking the consequences of 
taking an action, it is also important to track the consequences of not taking action.
42
  
Overview of the study 
 This study is designed to assess the acute pharmacological treatment given in the ED to 
older adults with AMI from a “structure-process-outcome” approach. The structure component is 
the ED computerized guideline reminders. The process component is the utilization of anti-
platelet agents and beta-blockers in the ED. Finally, the outcome component is in-hospital 
mortality and length of hospital stay. Our study is an exploratory study that is aimed to generate 
hypotheses for future study.   
Significance 
This study gives national estimates about older adult AMI care in the ED from 1992 to 
2010, which is the first to capture this long period of time of ED AMI care for older adults. 
Using the Donabedian model as a conceptual framework gave a holistic view of AMI care in 
older adults. The impact of having a computerized ED guideline reminder on the usage of 
antiplatelet agents and beta-blockers in the ED was evaluated, which is also a first. It also did 
describe the percentages of antiplatelet agents and beta-blockers used only in the ED, which was 
only done in few studies. Our study attempted to see the effect of AMI care in the ED on hospital 
outcomes, like in-hospital mortality and LOS. Finally, this study may help in increasing the 
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awareness of the ED health care professionals of older adults AMI care and the importance of 
incorporating computerized clinical decision support (CCDS) systems in the ED to remind health 
professionals about using guideline recommended therapies.  
Study Objectives  
This study had four primary objectives.  
1. Examine the temporal trend in the ED use of anti-platelet agents and beta-blockers in 
older adults with AMI in the US from 1992 to 2010 
2. Explore the association between a variety of predictor variables (demographic, clinical, 
visit, and hospital variables) and the ED use of anti-platelet agents and beta-blockers in 
older adults with AMI 
3. Evaluate the association between the ED use of anti-platelet agents and beta-blockers 
in older adults with AMI and the rate of in-hospital mortality and length of hospital stay 
4. Evaluate the association between the use of ED computerized guideline reminders and 
the ED utilization of anti-platelet agents and beta-blockers in older adults with AMI 
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Criteria for acute, evolving, or recent MI 
Either one of the following criteria satisfies the diagnosis for an acute or recent MI: 
 
(1) Typical rise and gradual fall (troponin) or more rapid rise and fall (CK-MB) of 
biochemical markers of myocardial necrosis with at least one of the following: 
(a) ischemic symptoms; 
(b) development of pathologic Q waves on the ECG; 
(c) ECG changes indicative of ischemia (ST segment elevation or depression); or 
(d) coronary artery intervention (e.g., coronary angioplasty). 
(2) Pathologic findings of an acute MI. 
 
CHAPTER 2 
 
Literature Review 
 
AMI overview 
AMI definition and classification 
 The literal meaning of myocardial infarction is the death of cardiac myocytes caused by 
prolonged ischemia.
1 
The World Health Organization (WHO) defined myocardial infarction in 
the Monitoring of Trends and Determinants in Cardiovascular Disease (MONICA) project 
published in 1994;
2
 however, this definition was updated by the European Society of Cardiology 
(ESC) and the American College of Cardiology (ACC) in 2000 because the WHO definition 
erroneously diagnosed patients with non-myocardial infarction even when actual cardiac damage 
had occurred.
1,3
 The updated definition of AMI is summarized in Figure 2.1.  
 
 
 
 
 
 
 
Figure 2.1: AMI definition of the European Society of Cardiology and the American 
College of Cardiology (Adapted from Ref. 1) 
MI: Myocardial infarction; CK-MB: Creatine kinase-MB; ECG: Electrocardiogram  
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Acute Coronary Syndromes (ACS) encompass a number of cardiovascular presentations 
which differ by the extent and duration of coronary occlusion, and include unstable angina (UA), 
non-ST-elevation myocardial infarction (NSTEMI), and ST-elevation myocardial infarction 
(STEMI).
1
 Both NSTEMI and STEMI are known collectively as AMI.
5
 Classification of AMI is 
made according to the changes found in the ECG. Figure 2.2 illustrates the differences between 
the two.
4
 AMI may be further classified according to the pathologic Q-waves. Patients with 
STEMI are more likely to have Q-waves in their ECG findings, or Q-wave MI (QMI). NSTEMI 
patients are less likely to have them, thus non-Q-wave MI (NQMI).
5
 The pathophysiology of 
ACS starts with the rupture of an atherosclerotic plaque followed by platelet adherence, 
aggregation, and activation of the clotting cascade, which will end in the formation of a clot 
filled with fibrin and platelets.
 4 
 
 
 
Figure 2.2: Differences in ECG between STEMI and NSTEMI (Adapted from Ref. 4) 
14 
 
AMI diagnosis and risk stratification 
 The typical symptom of AMI is chest pain, or more formally a midline anterior anginal 
chest discomfort that may radiate to the shoulder, down the left arm, to the back, or to the jaw.
 
There are other symptoms that may accompany chest pain, like nausea, vomiting, and shortness 
of breath.
 
There are no specific signs of AMI; hence, on physical examination, there will be no 
suggestive signs of AMI.
 
The main diagnostic procedure in detecting AMI is the 12-lead ECG, 
followed by a laboratory test of troponin and CK-MB, which are biochemical markers of 
myocardial cell death, to confirm AMI diagnosis. The 12-lead ECG should be done within 10 
minutes of patient’s presentation in the ED.4 More recent studies are recommending the 12-lead 
ECG to be done in the ambulance by the EMS staff.
6  
It is important to check the troponin and 
CK-MB level at least 3 times (in the ED, at 12 hours, and at 24 hours) because some patients 
may present to the ED with values below the level of detection. At 12 or 24 hours, they may 
have positive values of troponin or CK-MB.
4 
Figure 2.3 illustrates CK-MB and troponin levels in 
the blood across the days around AMI.
7
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Figure 2.3: Troponin and CK-MB levels in AMI patients 
Risk stratification in AMI is very important, as patients will be treated according to their 
risk stratification.
4 
Patients are stratified according to their symptoms, medical history, ECG 
readings, and troponin or CK-MB levels. Patients experiencing a STEMI are considered to be at 
high risk of mortality. On the other hand, when patients are experiencing a NSTEMI, their risk 
level is dependent on many factors. The Thrombolysis in Myocardial Infarction (TIMI) risk 
score is used to stratify NSTEMI patients
4-5,8
 and is  presented in Figure 2.4.
  
Low risk patients 
are usually monitored either in the ED or in a general ward. If values of troponin and CK-MB are 
still negative, they could be discharged. Moderate risk patients will be admitted either to the 
coronary care unit (CCU) or the step-down unit (SDU) to be monitored and treated. High risk 
patients should get early coronary angiography, which will be done in the cardiac catheterization 
laboratory.
4 
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Clinical presentation 
ST- segment depression( ≥0.5) 
2 episodes of chest discomfort within the 
past 24 hours 
Positive biomedical marker for infection. 
 
Past medical history 
Age ≥ 65 years 
  ≤ 3 risk factors for CAD 
 Hypercholesterolemia 
 HTN 
 DM 
 Smoking 
 Family history of positive CHD 
Known CAD (≥50% stenosis of coronary 
artery) 
Use of aspirin within the past 7 days  
Using the TIMI Risk Score 
One point is assigned for each of the seven medical history and clinical presentation 
findings. 
The score (point) total is calculated, and the patient is assigned a risk for experiencing 
the composite end point of death, myocardial infarction, or urgent need for 
revascularization as follows  
Low Risk 
TIMI risk score 0 – 2 
points 
Medium Risk 
TIMI risk score 3 –4 
points 
High Risk 
TIMI risk score 5 – 7 
points 
Other Ways to identify High – Risk Patients 
Other findings that alone or in combination may identify high – risk patients: 
 ST- segment depression. 
 Positive biomedical marker for infection. 
 Deep symmetric T- wave inversions (≥ 2mm). 
 Acute heart failure. 
 DM. 
 Chronic kidney disease. 
 Refractory chest discomfort despite maximal pharmacotherapy for ACS. 
 Recent MI within the past 2 weeks.  
 
Figure 2.4: TIMI score for NSTEMI (Adapted from Ref. 4) 
 Risk factors of getting an AMI are actually the same factors that are responsible of 
developing and progressing of atherosclerosis.
9 
There are established risk factors which have 
clear evidence that their modification is associated with a decrease in the risk of cardiovascular 
disease (CVD).
3
 These include dyslipidemias (high Low-Density Lipoprotein (LDL) or low 
High-Density Lipoprotein (HDL)), smoking, and hypertension.
3,9
 There are other established risk 
factors, but it is less clear if their modification is associated with a decrease in the risk of CVD.
3
 
These include diabetes mellitus, obesity, and physical inactivity.
3,9
 More recently, there are 
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emerging risk factors, which are mostly inflammatory markers like C-reactive protein and 
interleukins, but it is not clear whether their modification is associated with a decrease in the risk 
of CVD.
3
  
 Most AMI complications are life-threatening. The larger the infarct area, the higher the 
chance of experiencing complications. Also, the more ruptured plaques and the more coronary 
arteries involved, the worse the prognosis will be.
10 
The most life-threatening complication is 
cardiogenic shock. Almost 2-6% of AMI patients experience it. Patients presenting with STEMI 
are more likely to develop cardiogenic shock compared to patients with NSTEMI.
11-12 
Mortality 
almost reaches 60% when patients experience cardiogenic shock.
13 
Other complications are 
pericarditis, ventricular and atrial tachyarrhythmia, venous thromboembolism, heart block, 
valvular dysfunction, left ventricular (LV) free-wall rupture, bradycardia, stroke secondary to LV 
thrombus embolization, and heart failure. Many patients experience those complications even 
before reaching the hospital. For example, almost 25% of patients with AMI die before reaching 
the hospital because of ventricular fibrillation.
14
 
AMI treatment 
AMI acute interventional treatment   
Time is a crucial factor in AMI treatment. Minutes can mean the difference between a 
patient’s death and survival. Early restoration of blood flow to prevent further expansion of the 
infarct area is one of the most important short-term treatment goals.
4 
This can be achieved either 
by fibrinolysis or primary percutaneous coronary intervention (PCI). According to the 
ACC/AHA recommendations, STEMI patients should receive fibrinolysis within 30 minutes or 
primary PCI within 90 minutes.
15
 Both timely fibrinolysis and timely PCI are considered to be 
quality performance measures. Time to fibrinolysis is called “door-to-needle-time,” and time to 
18 
 
PCI is called “door-to-balloon-time”.15 STEMI patients should be transferred directly from the 
ED to the cardiac catheterization unit to undergo a coronary angiography with either a balloon 
angioplasty, placement of bare-metal stent, or drug-eluting intracoronary stent.
4  
PCI has been 
proven to be safer and more effective than fibrinolysis and also has fewer contraindications and 
side effects.
15-17 
Patients may undergo rescue PCI during their hospitalization if the fibrinolysis 
was unsuccessful, which is superior to repeated fibrinolysis.
18 
High risk NSTEMI patients should 
also be revascularized early either by a primary PCI or coronary artery bypass surgery 
(CABG).
5,17 
 
AMI acute medical treatment 
 Early pharmacotherapy is a pivotal component of AMI patients’ treatment. Both STEMI 
and NSTEMI patients receive the same pharmacological treatment. The standard treatment that 
should be given in the ED is intranasal oxygen (if oxygen saturation was less than 90%), 
morphine (for anginal pain), sublingual nitroglycerin, aspirin, a beta-blocker, and anti-coagulants 
(ex. unfractionated heparin or enoxaparin).
5,15
 It has been well established that both aspirin and 
beta-blockers improve survival.
19-20
 Hence, it was recommended that aspirin should be given as 
early as within 10 minutes of experiencing chest pain.
21
 Beta-blockers should also be given early 
either IV or orally.
5-15
 There has been some controversy around the IV administration of beta-
blockers because of the risk of cardiogenic shock when given to hemodynamically unstable 
patients.
22-23 
Early administration of aspirin and beta-blockers are both considered Class I 
recommendations in the ACC/AHA guidelines.
5,15,23
 Early administration of aspirin prevents 
thrombotic occlusion during the PCI procedure.
21 
 
 
19 
 
AMI secondary prevention 
The main therapeutic goal in AMI treatment is to prevent ventricular remodeling, which 
will lead to cardiac failure and ultimately death.
4,24 
Drugs that prevent ventricular remodeling 
improve survival. 
24 
Both beta-blockers and angiotensin converting enzyme (ACE)-inhibitors are 
well established to improve survival because both of them help prevent ventricular remodeling.
20, 
25-27 
Both should be continued indefinitely after their initiation in the hospital.
5,15,23
 Also, aspirin 
should be continued indefinitely after AMI, because it decreases the risk of death, recurrent MI, 
and stroke.
5,15,19,23 Statins  could be started in the hospital regardless of patient’s LDL cholesterol 
levels and also continued indefinitely because of their benefits in preventing total mortality, CV 
mortality, and stroke.
5,28-29 
Finally, most patients should also take clopidogrel as secondary 
intervention, but the duration of treatment differs according to how the patient was managed in 
the hospital.
4
 It should be administered indefinitely if the patient has aspirin allergy. It should 
only be administered for 9-months post AMI if the patient was managed medically and for 12-
months if the patient underwent PCI.
4
 
Older adults 
Challenges of treating AMI in older adults 
Chronological age alone has been shown to be an independent predictor of medical 
decision-making potentially impacting clinical care.
30
 One of the consequences of advanced age 
in AMI is the atypical clinical presentation of AMI in older adults, such as shortness of breath, 
functional and cognitive decline, fatigue, and non-diagnostic electrocardiogram (ECG). More 
importantly, chest pain, which is the landmark symptom of AMI, is seen less commonly in this 
population.
31,32 
This may lead to difficulty in facilitating early triage and diagnosis, which will in 
turn lead to a delay or underuse of recommended care.
31 
Additionally, older adults are known to 
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have a higher prevalence of comorbid conditions, which may further complicate their care.
31 
Patients presenting with comorbidities cause a challenge to physicians because they need to 
consider the contraindications and drug interactions and also weigh the risks and benefits before 
prescribing any drug. Another possible problem that may lead to the delay of care of older adults 
is the potential for inappropriate risk stratification. Since most older adults have a low prevalence 
of traditional, widely known, risk factors like ischemic heart disease, smoking, and family 
history of cardiovascular (CV) diseases, their risks of negative outcomes may be underestimated 
leading to a lower estimated urgency in care.
33
 
 It is important to mention that advanced age in and of itself is considered to be an 
independent predictor of increased mortality after AMI.
34 
There are several physiologic and 
structural changes in older adults that may yield negative outcomes.
35 
These include an increase 
in LV mass index, abnormalities of LV function, and decrease in systemic vascular 
compliance.
36-42
 Furthermore, there may be an increase in coagulation factors (VII, VIII, and IX) 
compared to the anticoagulation factors (antithrombin III and Protein C) that may lead to a 
greater risk of thrombosis, hence a greater infarct size.
42 
Older adults have increased risk of 
experiencing in-hospital AMI complications including congestive heart failure, atrial fibrillation, 
cardiogenic shock, and complete heart block.
30 
All of these complications may contribute to a 
longer hospital stay. As one study reported, older adults have hospital stays almost two times 
longer than younger adults.
33 
Another study found that the older the patient is the higher the 
mortality risk from AMI.
30
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Challenges of pharmaceutical care in older adults 
Older adults (i.e., those ≥65 years) represent about 13% of the US population yet account 
for 32% of all prescription drugs.
43,44
 Older patients are more likely to experience adverse drug 
events (ADEs). This is due to several factors, including overuse of medications, medication 
errors, non-adherence to medications, and inappropriate drug use.
45
 It has been reported that the 
incidence of ADEs in older patients varied from 5% to 35%, depending on the method used to 
define ADEs.
46,47
 ADEs may result in the need for additional medications, disability, decrease in 
quality of life, hospitalization, or death.
48
 One way of preventing ADEs in older patients is to 
avoid the use of potentially inappropriate medications (PlMs).
49
  
PIMs are drugs that have a poor risk-benefit profile due to aging-related physiologic or 
pharmacokinetic changes or have been correlated with poor outcomes in older patients.
49-51
 
Specific criteria for appropriateness of drugs in older adults were developed to identify these 
PIMs. The National Committee for Quality Assurance (NCQA) established a list of drugs to be 
avoided in the elderly (DAE) as part of the Healthcare Effectiveness Data and Information Set 
(HEDIS) measures.
52
 The NCQA HEDIS measures are based on the Beers list and the 2003 
update of that.
53,54
 In 2012, the American Geriatrics Society (AGS) updated Beers criteria for 
PIMs use in older adults.
55
 
Prescription of PIMs in older patients is highly prevalent ranging from 12% in 
community-dwelling elderly to 40% in nursing home residents.
56
 PIMs in older adults are 
associated with drug-related problems like hip or femur fracture, falls, hypoglycemia, as well as 
an increase in overall health care costs.
57 
Older adults are more vulnerable to PIM exposure in 
the ED because of the patients acuity and physician unfamiliarity with the patient.
58 
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ED utilization by older adults 
 
Older adults (≥65 years) are the fastest growing segment in the US population.59,60 As 
with any other health service, ED utilization by older adults will increase with this increase in 
population.
61 
It was found in a study using the NHAMCS database that older adults’ rate of ED 
utilization increased by 34% from 1993 to 2003.
61 
This will increase the problem of ED 
crowding, which will further complicate the ED management of the older adults.
61 
It will also 
increase the problem of ED boarding, ED boarding happens when patients are admitted to the 
hospital but are still awaiting their bed space, so they get boarded in the ED corridors until they 
get admitted, especially since most older adults coming to the ED will eventually be admitted to 
the hospital.
59,60,62 
ED crowding plus ED boarding may cause a delay in treatments and decline in 
the quality of care provided.
62
 Sadly, older adults may be significantly affected by this delay 
since they present with more severe conditions, more comorbidities, and higher levels of 
acuity.
63 
It was found that older adults are five times more likely to get a high-priority triage than 
younger adults.
62,64
 
 
The time from ED arrival to ED disposition is longer in older adults compared to younger 
adults.
  
Elderly patients were three times more likely to stay more than 1 day in the ED than 
younger patients (14.0% vs. 4.7%, p < 0.001).
63 
This may be attributed to the difficulty older 
adults face in trying to explain their clinical condition or history, plus the ambiguity of their 
physiological signs or symptoms.
63,65 
An older adult ED visit costs twice more than a younger 
adult because of higher drug charges, higher treatment charges, and more diagnostic 
procedures.
63,66-67 
The old-old (≥85) age group was found to have higher ED utilization.63,68 This 
was due to their lack of social support, poor living arrangements, and limited mobility.
63
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Previous investigations 
ED treatment of AMI  
 Few studies have documented ED utilization of aspirin and beta-blockers in AMI 
patients.
69-76 
A couple of studies defined drug use to be limited to ED administration only.
69-70, 74-
76 
Some of those studies considered that as a limitation because they were not able to capture pre-
hospital use of aspirin.
70,74,76 
Another study was only interested in the ED use of beta-blockers, so 
they did not need information about pre-hospital administration of drugs, because beta-blockers 
are not given by paramedics.
75 
Interestingly, in a Brazilian study, the documented average length 
of stay in the emergency room was 6.7 days.
69 
This suggests that emergency rooms there may be 
treated like an official ward. Hence, use of drugs in the ED in that study may not mean early use 
because a drug may have been started on the 5
th
 day of the stay in the ED. The other studies 
documented drug administration to be in the ED or 24 hours before ED arrival.
71-73 
Those studies 
aimed to capture aspirin administration by the EMS or by the patient at home. 
 Several studies had detailed clinical information about study patients.
71-73,75-76 
Patients 
who had contraindications to aspirin and beta-blockers could thus be excluded. Their utilization 
percentages were more accurate in comparing percentages across studies (see Table 2.1). 
Utilization varies greatly between studies primarily because they were done in different years. 
Earlier years had lower utilization rates compared to more recent years. The definition of 
administration and the depth of their clinical information can all affect utilization rates. The 
Brazilian study included an educational intervention for the ED staff about the implementation of 
clinical guidelines, so pre-intervention utilization rates and post-intervention utilization rates 
were available.
69
 In Table 2.1, the pre-intervention rates are reported for the sake of consistency 
with other studies. Only one study was nationally representative, but it was almost 10 years old.
74 
24 
 
Finally, only one study was specifically designed to study older adults, but the focus was beta-
blocker administration.
75
 All these studies examining ED treatment of AMI are summarized in 
Table 2.1. 
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Table 2.1: Summary of studies documenting ED utilization of aspirin and beta-blockers in AMI patients 
Reference  Study setting Time frame Total no. of 
AMI patients 
Mean age or 
Median age 
N(%) treated 
with ASA&BB  
Conclusion 
Escosteguy (2011)
69
 1 Hospital in 
Brazil 
2005-2006 78 Not mentioned (Pre-intervention) 
ASA: 68 (87%), 
BB: 40 (51%) 
(Post-intervention) 
ASA: 63 (96%), 
BB: 62 (94%) 
ED educational 
interventions 
increased ASA& 
BB utilization 
Takakuwu (2010)
70
 1 Hospital in 
Pennsylvania 
1999-2002 4,470  52.2 ± 15.8 ASA: 2,498 
(56%), BB: NA 
ASA utilization 
was not affected 
by age, race, sex 
Tsai (2010)
71
 58 Hospitals 
across 20 states 
2003-2006 3,819 65 (54 – 76)** ASA: 2,980 
(83%), BB: 945 
(55%) 
Utilization of 
ASA&BB was 
not ideal in ED 
Vinson (2007)
72
 5 Hospitals in 
California and 
Colorado 
2000-2002 2,215 74.3 ± 13.6 
(women) 
66.8 ± 11.9 (men) 
ASA: 1,639 
(80.5%), BB: 552 
(60.3%) 
ASA&BB 
utilization was 
suboptimal in 
ED 
Magid (2005)
73
 5 Hospitals in 
California and 
Colorado 
2000-2002 2,215 74.3 ± 13.6 
(women) 
66.8 ± 11.9 (men) 
ASA: 1,639 
(80.5%), BB: 552 
(60.3%) 
Older adults 
receive less 
ASA&BB in ED 
Pham (2007)
74
 NHAMCS 1998-2004 1,492 62 (aspirin 
users)*** 
64 (BB users) 
ASA: 596 (40%), 
BB: 231 (17%) 
ED use of ASA 
&BB was below 
expected goals 
Vega (2006)
75
 1 Hospital in 
Pennsylvania 
2001-2003 385 68 ± 14 ASA: NA, BB: 
129 (47%) 
Older STEMI 
patients receive 
less BB in ED 
Saketkhou (1997)
76
 4 Hospitals in 
Rhode Island 
1994 2,383 66 ± 14 ASA: 712 (30%), 
BB: NA 
ASA in the ED 
is underutilized  
*BB = beta-blockers, **Median was provided with IQR, ***SD was not provided, ED= Emergency department, AMI= Acute myocardial infarction 
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Inpatient treatment of AMI 
 
 Several studies have documented inpatient use of aspirin and beta-blockers in AMI 
patients.
77-90 
 Two studies looked at the trend of aspirin and beta-blockers utilization across time 
(1992-2002) with both noting an upward trend in utilization.
77,81  
Other studies were carried out 
to examine the effect of sex or race on aspirin or beta-blocker utilization.
79,81,82,90 
Their results 
varied.
 
One study was interested to know if diabetic AMI patients had different utilization rates 
of aspirin compared to non-diabetic AMI patients.
83
 The authors found that patients who had 
diabetes were less likely to get aspirin compared to patients who did not have diabetes.
83 
Another 
study examined the effect of type of insurance
 
on the utilization of aspirin and beta-blockers.
88 
It 
found that patients in health maintenance organizations were more likely to receive aspirin and 
beta-blockers than fee-for-service patients.
88  
Most of the studies examined the effect of age on utilization of aspirin and beta-blockers, 
and all hypothesized older patients were less likely to receive aspirin or beta-blockers.
80,84-87,90
 
All studies  found evidence supporting their hypothesis. Utilization rates in all of these studies 
were very similar. Aspirin rates were generally above 80%, and beta-blockers were between 60% 
and 70%.
77,79-84,88 
Some of the older studies (1990-1996) had lower beta-blocker utilization 
rates.
85-87, 89-90
 During that time period there was not much emphasis on beta-blocker use for 
secondary prevention in AMI patients. Studies examining inpatient use of aspirin and beta-
blockers are summarized in Table 2.2. 
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Table 2.2: Summary of studies documenting inpatient utilization of aspirin and beta-blockers in AMI patients 
Reference  Study setting Data years Total no. of 
AMI patients 
Mean age or 
Median age 
% treated with 
ASA & BB 
Conclusion 
Gottlieb 
(2007)
77
 
25 Hospitals in 
Israel 
1992-2002 1,475 80.8 ± 5.1* ASA: 87, BB: 70* ASA&BB utilization 
had a positive trend 
across 1992-2002 
Marti 
(2007)
78
 
1 Hospital in 
Spain 
2000-2004 Not 
mentioned 
Age range (80-97) ASA: 55, BB: 4 very low use of ASA 
&BB in patients ≥85 
Mehta 
(2006)
79
 
GUSTO and 
ASSENT trials 
1992-2000 32,419 61.1±12.2 (Whites) 
57.0±12.1 (Blacks) 
(Whites)  
ASA: 93.2, BB: 80.8  
(Blacks)  
ASA: 93.7, BB: 82.6  
ASA&BB utilization 
was not different 
between white and 
black patients 
Avezum 
(2005)
80
 
102 hospitals in 
14 countries  
1999-2002 24,165 50% of the sample 
are 55-74 years** 
(age = 65-74)  
ASA: 92, BB: 78 
(age ≥85)  
ASA: 88, BB: 65*** 
ASA&BB utilization 
was suboptimal in 
older adults 
Vaccarino 
(2005)
81
 
NRMI† 
database 
1994-2002 598,911 66.4 (White men) 
74.0 (White women) 
61.3 (Black men) 
67.3 (Black women) 
(White men)  
ASA: 84, BB: 67 
(White women) 
ASA: 79, BB: 63 
(Black men)  
ASA: 84, BB: 68 
(Black women) 
ASA: 78, BB: 65 
Use of ASA&BB did 
not vary according to 
race and sex 
Blomkalns 
(2005)
82
 
CRUSADE†† 
database 
2000-2002 35,875 68 (56-78) ††† (Males) 
ASA: 91.6, BB: 77.7 
(Females) 
ASA: 89.6, BB: 75.9 
Use of ASA&BB did 
not vary according to 
sex 
Collinson 
(2004)
83
 
PRAIS-UK‡ 
database 
1998-1999 1,046 66 ± 12 (Diabetics) 
ASA: 81, BB: NA  
(non-Diabetics) 
ASA: 88, BB: NA  
Diabetics had lower 
ASA utilization than 
non-diabetics 
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Stern 
(2004)
84
 
26 Hospitals in 
Israel 
2000 2,133 70 ± 2 (65-74) 
81 ± 5 (≥75) 
(age = 65-74)  
ASA: 96, BB: 76 
(age ≥75) 
ASA: 95, BB: 64  
Older adults are less 
treated with 
ASA&BB than 
youngers adults 
Rathore 
(2003)
85
 
CCP‡‡ 
 database  
1994-1996 146,718 76 ± 7 (age = 65-69) 
ASA: 78, BB: 55 
(age ≥85) 
ASA: 64, BB: 38 
Older adults are less 
treated with 
ASA&BB than 
youngers adults 
Ruiz-Bailen 
(2002)
86
 
119 Hospitals in 
Spain 
1995-2001 17,761 65.2 ± 12.3 ASA: 97, BB: 44 
 
ASA&BB were 
underutilized in 
older adults 
Mehta 
(2001)
87
 
CCP‡‡ 
database 
1994-1996 163,140 Not mentioned (age = 65-69) 
ASA: 84, BB: 52 
(age ≥85) 
ASA: 69, BB: 33 
Older adults had 
lower utilization 
rates of ASA&BB 
Soumerai 
(1999)
88
 
20 Hospitals in 
Minnesota 
1992-1996 2,340 50% of the sample 
are ≥75 years 
(HMO) 
ASA: 88, BB: 73 
(FFS) 
ASA: 83, BB: 62 
HMO patients were 
more likely to get 
ASA&BB than FFS 
patients 
Marciniak 
(1998)
89
 
Hospitals in AL, 
CN, IO, WS 
1992-1996 23,535 75.3 ASA: 84, BB: 47 ASA&BB were 
suboptimaly used 
Stone 
(1996)
90
 
TIMI III ‡‡‡ 
Registry 
1990-1993 3,318 63.8 ASA: 82, BB: 45 Older adults are less 
treated with ASA& 
BB than younger 
adults 
*Numbers are of most recent year (2002), **No mean age was reported, ***NRMI= National Registry of Myocardial Infarction, †Youngest and oldest groups 
were only reported, ††CRUSADE= Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes with Early Implementation of the 
American College of Cardiology/American Heart Association Guidelines initiative, ††† Median and IQR, ‡ PRAIS-UK= Prospective Registry of Acute Ischemic 
Syndromes in the United Kingdom, ‡‡ CCP= Cooperative Cardiovascular Project, ‡‡‡ TIMI= Thrombolysis In Myocardial Infarction, AMI = Acute myocardial 
infarction, BB = beta-blockers 
 
29 
 
AMI treatment effect on mortality 
 
 Several studies examined the effect of aspirin and beta-blockers on mortality, but none 
looked at their effect on length of hospital stay (LOS).
91-100
 Most of studies were interested in the 
effect of aspirin and beta-blockers on in-hospital mortality.
91,92,95,96,98,99  
The results from these 
studies varied.
 
A couple of studies looked at the effect of aspirin on 30-day mortality post-
AMI.
94,100
 Both found that aspirin significantly lowered 30-day mortality.
94,100 
Another studies 
looked at the effect of aspirin or beta-blockers on mid-to-long-term mortality.
 
One study 
examined the effect of beta-blockers on midterm mortality (mean follow-up almost 2 years) and 
found that patients receiving a beta-blocker had a lower midterm mortality.
93 
The other study 
evaluated 1-year mortality post-AMI and found that both aspirin and beta-blockers 
administration resulted in lower 1-year mortality rates.
97 
 
 Some studies looked at the cumulative effect of all acute treatment given to the patient on 
in-hospital mortality.
95,98 
One examined the cumulative effect of acute medical treatment 
(aspirin, beta-blockers, oral anti-coagulants, and oral anti-platelets) and found that patients 
treated acutely with these drugs had lower in-hospital mortality.
95 
The other examined the 
cumulative effect of both acute medical and interventional treatment (e.g. PCI) finding that 
patients had lower in-hospital mortality rates when they were treated acutely by those drugs.
98  
Several studies were interested in the effect of acute treatment of aspirin and beta-
blockers on mortality, which was defined by most studies to be administered in the first 24 
hours.
91,92,95,96,98,99 
These studies all evaluated the effects of aspirin and beta-blockers on in-
hospital mortality, which may explain why they only looked at acute treatment. All these studies 
are summarized in Table 2.3 
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Table 2.3: Summary of studies documenting the effects of utilization of aspirin and beta-blockers in AMI patients on mortality  
Reference  Study setting Data years Total no. of 
AMI patients 
Mean ±  SD age or 
Median (IQR) age 
Effect of aspirin 
on mortality 
Effect of BB   
on mortality 
Filardo (2011)
91
 14 Hospitals in 
Texas 
2002-2008 6,826 65.3 ± 14.7* OR=0.37 (95% 
CI: 0.22-0.65) 
OR=0.24 (95% 
CI: 0.11-0.52) 
Medina (2011)
92
 GWTG-CAD 
database*** 
2000-2009 156,677 66.4 ± 14.7 OR=0.88 (95% 
CI: 0.76-1.02)** 
OR=0.87 (95% 
CI: 0.77-0.98) 
Kashima (2010)
93
 1 Hospital in 
Japan  
2002-2008 77 86 ± 4 NA HR=0.34 (95% 
CI: 0.12-0.99) † 
Radcliff (2010)
94
 CCP database 1994-1995 120,032 76.7 ± 7.4 OR=0.57 (95% 
CI: 0.54-0.60) †† 
NA 
Peterson (2008)
95
 NRMI database 1990-2006 2,515,106 65.5 ± 14 ††† OR=0.980 (95% CI: 0.975-0.984) ‡ 
for both aspirin and beta-blockers  
Wienbergen 
(2007)
96
 
MITRAPLUS‡‡ 
German registry 
1994-2005 17,809 65.3 ±  NA NA OR=0.70 (95% 
CI: 0.61-0.81)   
Yan (2006)
97
 9 provinces in 
Canada 
1999-2001 4,627 46% of the sample 
is less than 65 years  
OR=0.48 (95% 
CI: 0.36-0.65)   
OR=0.72 (95% 
CI: 0.56-0.93)   
Alexander 
(2005)
98
 
CRUSADE 
database 
2001-2003 56,963 58% of the sample 
is older than 65 
Acute aspirin and BB associated with 
lower rates of hospital mortality (OR 
not provided) 
Krumholz 
(1999)
99
 
CCP database 1994-1995 58,165 75.1±  NA NA OR=0.81 (95% 
CI: 0.75-0.87)   
Krumholz 
(1995)
100
 
CCP database 1992-1993 10,018 NA OR=0.73 (95% 
CI: 0.65-0.82)   
NA 
*Results of year 2008, **Comparison between (65-79) age group and (<65) age group, *** GWTG-CAD= Get with the Guidelines-Coronary Artery Disease, 
†Results of the non-PCI group, †† Results of the community-dwelling older adults, ††† Results of most recent years 2003-2006, ‡This OR represents the effect 
of all acute treatment (aspirin, beta-blockers, anti-coagulants, and anti-platelets) on mortality, ‡‡ MITRA= Maximal Individual Therapy of Acute Myocardial 
Infarction registry, ‡‡‡ No SD available, the mean age is for the beta-blocker users, CI= Confidence intervals, CCP= Cooperative Cardiovascular Project, OR= 
Odds ratio, NRMI= National Registry of Myocardial Infarction, CRUSADE=  “Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse 
Outcomes with Early Implementation of the ACC/AHA Guidelines”, NA= Not available, SD= Standard deviation
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ED structure effect on AMI treatment 
 
 Only two studies evaluated ED structure effects on AMI treatment.
101-102 
Both studies 
used national databases: CRUSADE
101
 and CCP
102
. One study conducted a survey on 316 
CRUSADE participating hospitals from 2001 to 2003.
101
 This survey targeted ED physicians and 
nurse coordinators to answer certain questions about the ED structure. Only 136 hospitals 
(representing 20,856 patients) replied with both the physician and the nurse response. This study 
had valuable input about the relationship between ED structure and ACC/AHA guidelines 
concordance (ECG within 10 minutes, aspirin and beta-blockers at arrival, use of heparin and 
glycoprotein IIb/IIIa inhibitors within 24 hours). They found that the strongest determinant of 
guideline concordance was having an ED administration highly committed to quality initiatives 
(OR: 1.58, 95% CI: [1.45-1.72]). They also found that having adequate nursing in the ED yields 
better concordance with the guidelines (OR: 1.09, 95% CI: [1.04-1.15]) because it allows more 
time with each patient.
 
Finally, their most relevant result to the current study is that one of the 
main determinants of guideline concordance is having an algorithm, not specified whether it is 
computerized or not, available in the ED for AMI care (OR: 1.08, 95% CI: [1.03-1.12]).
 
 
The other study was only interested in aspirin and beta-blocker administration.
102
 It 
examined the organizational infrastructure of 44 hospitals in Kansas participating in the CCP 
project to see whether organizational infrastructure affects administration of aspirin and beta-
blockers. They found that almost 68% of hospitals have an ED protocol, where 43% of those 
protocols specified aspirin and 18% specified beta-blockers. Having protocols that specified 
aspirin and beta-blockers in the ED significantly affected beta-blocker administration on 
admission (OR: 2.14, 95% CI: [1.25-3.77]), but it did not affect aspirin on admission (OR: 1.31, 
95% CI: [0.87-2.00]).
 
They also found that almost 54% of the hospitals had an ED standardized 
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order set where 34% of those sets specified aspirin and 20% specified beta-blockers.
 
Having 
those standardized sets in the ED significantly affected aspirin administration on admission (OR: 
1.57, 95% CI: [1.01-2.48]), but it did not affect beta-blocker administration on admission (OR: 
1.57, 95% CI: [0.87-2.93]).
 
Unlike the previous study, they did not find that having an ED 
administration committed to quality was a determinant of aspirin or beta-blocker 
administration.
102
 
No studies examined the effect of computerized clinical decision support (CCDS) 
systems in the ED on AMI treatment. Several studies have looked at the effect of CCDS in other 
disease states and in different settings. 
103-106 
Few studies have examined the effect of CCDS 
system in the ED.
107-108 
One study used the CCDS system in the ED to screen for HIV. They 
found that using the CCDS for this purpose increased the detection rate of HIV and hence helped 
in treating undetected HIV cases
107 
The other study found that when incorporating pneumococcal 
vaccination reminders in the CCDS system in the ED, it helped to overcome existing barriers that 
the health professionals had towards pneumococcal vaccination.
108
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Literature gap and significance 
 Based on this extensive literature review, most of the studies were not specifically 
focused on older adults (>65). Also, very few studies evaluated care in the ED where the AMI 
patient is first evaluated and treated. Several studies examined the effect of acute (ED plus 
inpatient) AMI care on mortality, but none looked specifically at the effect of ED care on 
mortality. None of these studies looked at the effect of ED care on length of hospital stay. 
Finally, only two studies looked at the effect of ED structure on AMI care in the ED, but none 
looked at the effect of CCDS in the ED on AMI care. 
This study will give national estimates about older adult AMI care in the ED from 1992 
to 2010. This is the first study to capture this long period of time of ED AMI care for older 
adults. This study uses the Donabedian model for quality measurement, which gives a holistic 
view of AMI care in older adults.  This study will evaluate the impact of having a computerized 
reminder to prompt ED staff to use guidelines, on the usage of guideline concordance therapy in 
the ED.  This study will also reveal the percentages of drugs use only in the ED, which was only 
done in few studies. This study will also attempt to see the effect of care in the ED on hospital 
outcomes, like in-hospital mortality and LOS. Finally, this study may help increase ED health 
care professionals’ awareness of older adults AMI care and the importance of incorporating 
CCDS systems in the ED to remind health professionals about using guideline recommended 
therapies.  
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CHAPTER 3 
 
Methods 
 
Data source 
 
The National Hospital Ambulatory Medical Care Survey (NHAMCS), one of the 
databases available from the National Center for Health Statistics (NCHS), was used for this 
study. NHAMCS was selected instead of the National Ambulatory Medical Care Survey 
(NAMCS) because ED data is only available in the NHAMCS database. NHAMCS includes a 
national probability sample of visits to the emergency and outpatient departments of 
noninstitutional general and short-stay hospitals in the 50 States and the District of Columbia.
1
 
The survey design is a four-stage probability sampling approach with samples of primary 
sampling units (PSUs), hospitals within PSUs, clinics and emergency service areas within 
hospitals, and patient visits within clinics and emergency service areas.
1 
The PSU consists of a 
county, a group of counties, county equivalents (such as parishes and independent cities), towns, 
townships, minor civil divisions (for some PSUs in New England), or a metropolitan statistical 
area (MSA).
2
 The PSUs are comprised of a probability subsample of the PSUs used in the 1985-
94 National Health Interview Survey (NHIS).
2
 The hospitals are divided into 16 subsamples; 
each subsample has a data collection period of 4 weeks. In year 2010, the most recent year 
available, about 112 PSUs, 488 hospitals, 388 EDs, and 100 visits in each ED were sampled. The 
validity and quality of this survey and database have been assessed in more than 100 previous 
publications.
2
 
Given the sampling method, the results from NHAMCS should be nationally 
representative. All of the analyses should be weighted to get national estimates. In order to get 
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reliable national estimates, the estimates must be based on at least 30 cases and the estimates 
should have a relative standard error of less than 30%.
1 
 Data in NHAMCS are abstracted from patient records by a trained nurse who works in 
the hospital. A nurse is chosen because she/he is more acquainted with the hospital’s records, 
which makes it easier to abstract the information. A field representative then checks on the 
quality of the data collection and is concerned mostly with the completeness of the form. 
Incomplete data items are sometimes imputed using a hot deck procedure by assigning a value 
from a randomly selected patient record form with similar characteristics. Then, the data is sent 
to be coded by a trained medical coding personnel from the Division of Data Processing at the 
NCHS computer facility in Research Triangle Park North Carolina.
2 
 
 
Study population 
 
Data for this study were obtained from1992 to 2010. Patients who were included in this 
study had to have an admission diagnosis of AMI (ICD-9-CM code 410.xx) and be at least 55 
years of age. Admission diagnosis was chosen instead of discharge diagnosis because this study 
is interested in the medications given in the ED, which are prescribed based on the patient’s 
admission diagnosis. To ensure the accuracy of the admission diagnosis, patients were excluded 
if their diagnosis was considered questionable (rule-out). It is important to note here that from 
year 1992 to 1996 the variable indicating whether the diagnosis is probable or not was not 
available, hence these years had larger numbers of participants; meaning it is probable that some 
of these cases did not have a confirmed AMI diagnosis. Another reason for choosing the 
admission diagnosis is for consistency purposes; the admission diagnosis was available in all the 
years but discharge diagnosis was only available from year 2005 onwards.  
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Study design 
 
This study used a cross-sectional design for all of the aims. The first aim explored the 
trend in the utilization of antiplatelet agents and beta-blockers from 1992-2010. The second aim 
explored the bivariate associations between receiving antiplatelet agents or beta-blockers and 
demographic, clinical, visit, and hospital characteristics. The third aim determined whether an 
association existed between receiving antiplatelet agents or beta-blockers and in-hospital 
mortality and length of hospital stay. In this aim, only years 2005 onwards were used because 
these are the only years that have discharge data. Moreover, only patients who are admitted to 
the hospital will be used in this aim, meaning patients who died in the ED or patients who were 
transferred to other hospitals will be excluded. The fourth aim evaluated the association between 
the use of a computerized guideline reminder in the ED and the ED usage patterns of antiplatelet 
agents and beta-blockers.  
Data extraction and manipulations 
 
Drug data variables 
            The drugs of interest in this study are: antiplatelet agents (aspirin, clopidogrel, 
ticlopidine, and dipyridamole) and beta-blockers (all beta-blockers available in NHAMCS, 
summarized in Table 3.1). These drugs were chosen because they were recommended as part of 
acute medical care for an AMI in the ACC/AHA guidelines. In these guidelines, the use of 
aspirin and beta-blockers in the first 24 hours is considered a quality indicator. It was also 
mentioned in the guidelines that if aspirin was contraindicated, clopidogrel, ticlopidine, or 
dipyridamole can be used instead. An important matter to note here is that in 2006, NHAMCS 
switched from the Food and Drug Administration’s (FDA) National Drug Code Directory (NDC) 
to Lexicon Plus®, a proprietary database of Cerner Multum, Inc., to code characteristics of drugs 
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listed on the patient record.
3
A drug conversion file and a SAS program were supplied by 
NHAMCS team in order to recode the years before 2006 to Lexicon Plus® for researchers 
interested in merging data before 2006 with year 2006 and after. The drug codes used in this 
study are summarized in Table 3.1. 
Table 3.1: Drug codes  
Drug group  Drug name and codes 
Antiplatelet agents Aspirin (d00170) 
Clopidogrel (d04258) 
Ticlopidine (d00514) 
Dipyridamole (d00213)  
Beta-blockers Metoprolol (d00134) 
Atenolol (d00004) 
Carvedilol (d03847) 
Nadolol (d00018) 
Metipranolol (d00297) 
Betaxolol (d00176) 
Bisoprolol (d00709) 
Propranolol (d00032) 
Acebutolol (d00128) 
Pindolol (d00137) 
Timolol (d00139) 
Esmolol (d00224) 
Carteolol (d00708) 
  
 
Demographic data variables 
           Age was a continuous variable that was recoded into a categorical variable. This variable 
grouped patients into older or equal to 65 and younger than 65. Sex was coded into males and 
females. Ethnicity was originally coded as Hispanic and non-Hispanic. For patient race, 
NHAMCS had a recode for all years that defined race as white, black, and other, which was used 
for this study. Patient residence was defined as private, nursing home, institutions, and homeless 
beginning in 2005; however, the years earlier defined patient residence as nursing home or not 
nursing home. For consistency purposes, the nursing home and not nursing home coding was the 
one chosen to be used for this study. The source of payment variable was recoded into the 
following categories: Medicare, Medicaid, private insurance, and other. The “other” category 
included workers compensation, charity, and self-pay.  
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Clinical data variables 
            Systolic blood pressure (SBP) and heart rate (HR) were continuous variables that were 
recoded to categorical variables. For the SBP variable, patients who had a SBP that is less than 
or equal to 90 mmHg were considered to be hypotensive; more than 90 mmHg was not 
hypotensive. For the HR variable, patients who had an HR that is less than or equal to 60 bpm 
were considered to be bradycardic; more than 60 bpm was not bradycardic. These variables were 
defined this way to identify patients who had a potential contraindication to beta-blockers. The 
clinical presentation of interest for these patients is whether or not they had chest pain. 
NHAMCS has a variable that specifies the patients’ reason for visit, which coded the patients’ 
verbatim of why they are visiting the ED. The chest pain code was looked up, and then a variable 
specific to chest pain was created.  
The triage variable presented some challenges as the coding changed three times across 
the study period. A new variable was created to put all these changes into consideration by 
grouping triage into two categories: high and low. High triage patients were given a priority to be 
seen within 1 hour or less; low triage patients were given a priority to be seen within 1-2 hours. 
The number of procedures done and number of diagnostic services done were continuous 
variables. Cardiac enzyme test and cardiac monitor test variables were both coded as yes/no 
variables, the actual result of the test is not provided. 
Visit Data variables 
            The time variable was recoded to three categories: day, evening, and night. Day was 
considered to be 8:00 am to 3:59 pm; evening was considered to be 4:00 pm to 11:59 pm; and 
night was considered to be 12:00 am to 7:59 am. The variable representing the day of the week 
of the visit was recoded to weekday and weekend. Mode of arrival variable coding changed 
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across the years, some years had more than one transport category and others had only 
ambulance or not. Hence, it was recoded into arrival by ambulance or not, for consistency 
purposes throughout the years. The provider seen variable was also collected differently across 
the years with different variable names, so it was defined into the following categories; 
physician, physician assistant, resident physician, nurse practitioner, and nurse (RN/LPN). The 
provider seen variable is coded in a way that you can select all that apply. For example, a patient 
can be seen by a nurse, a physician, and resident. Patients’ discharge variables were only 
available starting year 2005. Discharge status was defined as alive or dead. Length of hospital 
stay (LOS) was a continuous variable expressed in days. 
Hospital Data Variables  
            Hospital ownership and Metropolitan Statistical Area (MSA) variables had different 
names across the years, so they had to be recoded for consistency purposes. Hospital ownership 
had 3 categories: proprietary (for-profit), government (non-federal), and voluntary (not-profit). 
MSA was two categories: MSA and non-MSA. Hospital region was expressed as Northeast, 
Midwest, South, and West.  The computerized guideline reminder variable was only available 
starting year 2005 and was a simple yes/no variable, there was no further explanation of that 
variable to show its actual content. 
Design variables 
            In order to get national estimates and to account for the four-stage survey sampling 
design, design variables provided from NHAMCS must be used in all analyses. The first design 
variable is patient weight (PATWT), the second is stratum weight (CSTRATM), and the third is 
PSU weight (CPSUM). Years prior to 2002 did not have these design variables; hence, 
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NHAMCS has provided a SAS program to add these design variables to those years for 
researchers interested in merging data before 2002 with year 2002 and after. 
Outcome Variables 
 
 For aims 1, 2, and 4, the outcome variables of interest are antiplatelet agent utilization 
and beta-blocker utilization. Utilization for each drug class is expressed by yes/no for each visit, 
so they it is visit-level data. For aim 3, the outcome variables are in-hospital mortality and length 
of hospital stay.  
Predictor Variables 
 
 Predictors will be grouped into patient demographics (sex, race, ethnicity, residence, and 
source of payment), patient clinical characteristics (triage level, SBP, HR, clinical presentation, 
number of procedures done in ED, number of diagnostic services done, whether they did a 
cardiac enzyme test, and whether they had cardiac monitoring), visit characteristics (time and 
day of arrival, provider seen, transport used to get to the hospital), hospital characteristics 
(hospital region, hospital ownership, MSA, and availability of computerized guideline 
reminders). Predictor variables summary and coding are presented in Table 3.2. 
 
Table 3.2: Predictor Variables 
Predictor Variables Coding  
Patient Demographics 
Sex Male,  Female 
Race White, Black, Other 
Ethnicity Hispanic, Not Hispanic 
Patient residence Nursing home, Other 
Expected source of payment Medicare, Medicaid, Private, Other 
Patient Clinical Characteristics 
Systolic blood pressure (SBP) Hypotensive “≤ 90mmHg” (Yes/No) 
Heart rate (HR) Bradycardic “≤60bpm” (Yes/No) 
50 
 
Number of procedures done during 
the ED visit 
Actual number.  
Number of diagnostic services 
done during the ED visit 
Actual number.  
Patient clinical presentation Chest pain (Yes/No) 
Triage level High priority (1-60 min), Low priority (>60 
min) 
Cardiac Enzyme test Yes, No 
Cardiac Monitor test Yes, No 
Visit Characteristics 
Time of arrival Day (8am-3:39pm), Evening (4pm-
11:59pm), Night (12am-7:59am) 
Day of Arrival Weekday, Weekend 
Mode of transport Ambulance, Other 
Provider seen Physician, Physician Assistant, Resident, 
Nurse Practitioner, Nurse (RN/LPN) 
Hospital Characteristics 
Hospital region Northeast, Midwest, South, West 
Hospital ownership Proprietary, Government, Nonprofit 
Metropolitan Statistical Area MSA, non-MSA 
ED Computerized guideline 
reminders 
Yes, No 
 
Patient Demographics 
  
Several studies have shown that patient demographics such as gender and race can be 
important predictors of AMI treatment.  Females and black patients have been shown to be 
undertreated.
4-7
 Patient’s residence also acts as a predictor of AMI treatment. A recent study 
showed that patients admitted from nursing homes were less likely to receive treatment for 
AMI.
8
 Furthermore, the effect of source of payment is also of importance on AMI care. A 
nationally representative study has shown that patients with private insurance were more likely 
to have appropriate AMI care.
9 
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Patient Clinical Characteristics 
 
Patient clinical characteristics can be considered important predictors of AMI treatment. 
A recent study showed that if a patient with AMI was given a low-priority triage level, it was 
associated with delay in treatment, longer hospital stay, and higher mortality.
10
 A multi-center 
study that looked at chest pain in older adults found that it is more difficult to diagnose acute 
chest pain in older adults, so this may lead to a lower-priority triage and hence delayed care.
11 
Visit Characteristics 
 
The timing of the ED visit, both time of day and the day of the week, has been shown to 
be an important consideration. A recent study showed that patients admitted off-hours (i.e., 4pm 
to 7:30am on weekdays or all day on weekends) were more likely to have in-hospital mortality 
and also experience a delay in AMI care.
12
 From the standpoint of day of arrival, a study showed 
that patients admitted during the weekend had higher in-hospital mortality, which may be 
explained by the disparities in resources and expertise of healthcare providers working during 
weekends when compared to weekdays.
13 
 
Hospital Characteristics 
 
Some hospital characteristics like, hospital region and hospital ownership may have an 
effect on AMI care. A study found that patients in the northeast region were more likely to get 
better quality of AMI care.
9
 In the same study, it was shown that patients who were in 
governmental hospitals were less likely to receive appropriate treatment for AMI.
9
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Statistical analysis 
 
Descriptive statistics were used to describe the baseline characteristics for our patients. 
Continuous variables were expressed as the weighted mean ± standard deviation (SD) and the 
95% confidence intervals (CI) of the mean. The SURVEYMEANS procedure will be used for 
continuous variables. Categorical variables were expressed as the weighted frequency and the 
row percent and 95% CI of the row percent. The SURVEYFREQ procedure was used for 
categorical variables. The a priori significance level is set to two-sided p-value of 0.05. SAS 
version 9.3 was used for all analyses. 
In this study, the aim was to generate hypotheses, so predictive model building strategies 
were not used. Given the exploratory nature of this study, the focus is on adjusting for potential 
confounders and providing insight for further studies in this area.  
For the first aim, which was to examine the temporal trend in receiving antiplatelet agents 
and beta-blockers, the SURVEYLOGISTIC procedure was used to conduct a logistic regression 
analysis. Two models will be used, one for antiplatelet agents as the outcome variable, and the 
other with beta-blockers as the outcome variable. The predictor variable for both models was 
year as a continuous variable, ranging from 1992 to 2010. The odds ratio was used to explain the 
magnitude and direction of the trend. 
 For the second aim, the effect of demographic, clinical, visit, and hospital characteristics 
on receiving antiplatelet agents and beta-blockers was examined. A bivariate logistic regression 
was carried out using the SURVEYLOGISTIC procedure between the outcome variables, which 
was the utilization of antiplatelet agents or beta-blockers, and the predictor variables. The odds 
ratio was used to express the magnitude and direction of the relationship. Then, if the 
relationship is significant, a multivariate logistic regression will be carried out controlling for 
53 
 
age, sex, race, and year. These variables were chosen because they have strong evidence 
confirming their effect on anti-platelet agent and beta-blocker utilization rates, plus they are 
available most of the time for all patients.
4-7
  
For the third aim, the first outcome examined was in-hospital mortality. Given the low 
mortality rate, only 15 cases of mortality, it was not possible to carry out a Kaplan-Meir Survival 
Analysis nor a logistic regression analysis. Hence, a chi-square test was used to determine 
whether the patients who took an antiplatelet agent or beta-blocker were different from the ones 
who did not in their rate of in-hospital mortality. The SURVEYFREQ procedure with CHISQ 
option was used to carry out the chi-square test. The second part of the third aim is looking at 
whether guideline-concordant therapy has an effect on length of hospital stay. Since the 
dependent variable in this analysis is continuous, the SURVEYREG procedure was used to carry 
out a linear logistic regression between LOS and antiplatelet agents or beta-blockers. The 
regression coefficient was used to express the magnitude and direction of the relationship. 
For the last aim, the association between the availability of a computerized guideline 
reminder in the ED and the ED utilization of antiplatelet agents and beta-blockers was evaluated. 
Like the first aim, a bivariate logistic regression was conducted using the SURVEYLOGISTIC 
procedure in SAS. The odds ratio was used to express the magnitude and direction of the 
relationship. If the relationship is significant, then a multivariate logistic regression was carried 
out adjusting for age, sex, race, and race. 
All the analyses were weighted to get national estimates. In order to get reliable national 
estimates, our estimates must be based on at least 30 cases. The other requirement for reliability 
is that estimates should have a relative standard error of less than 30%, was not achievable in this 
study. We reached this conclusion after long discussions with NHAMCS statisticians. We 
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concluded that our data may be highly clustered because only a very few EDs may account for 
most visits for our specific diagnosis, which will mean that our standard errors will always be 
high because of that clustering. The SAS code for the data manipulation and data analysis is 
provided in Appendix A. 
Human subject protection and data privacy 
 
Data files were available from the National Center for Health Statistics, which codes and 
encrypts the data to prevent identifiability resulting in a dataset compliant with the Health 
Insurance Portability and Accountability Act of 1996. This study qualified for exemption 
according to 45 CFR 46.101(b) Category 4 at Virginia Commonwealth University internal 
review board (IRB). (VCU IRB#: HM14455). A copy of the IRB Approval form can be found in 
Appendix B. 
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CHAPTER 4 
 
Results 
 
Descriptive Results 
 
A total of 1771 visits (weighted: 6.1 million visits) were eligible for this study. Almost 
3.33 million (54%) [95% CI: 51.7% to 57.1%] of our population were females with a mean age 
of 72.1 (±13.7) years. This population is 87% (5.32 million) white [95% CI: 84.9% to 89.1%] 
and 94% (5.33 million) non-Hispanic [95% CI: 91.8% to 95.3%]. A summary of patients’ 
demographics is presented in Table 4.1.  
Table 4.1: Patient Demographics 
Patients’ Demographics 
Total population = 6,118,050 
Unweighted 
Frequency 
Weighted Frequency 
(%) 
95% CI of the  
% 
Age 
Sex 
      - Female 
      - Male 
--- 
 
951 
820 
72.1 (±13.7)* 
 
3,329,349 (54.4) 
2,788,701 (45.6) 
[71.4 – 72.7] 
 
[51.7 – 57.1] 
[42.9 – 48.3] 
Race 
      - White 
      - Black 
      - Other** 
 
1,519 
179 
73 
 
5,323,371 (87.0) 
   589,075 (9.6) 
   205,604 (3.4) 
 
[84.9 – 89.1] 
[7.9 – 11.4] 
[2.1 – 4.6] 
Ethnicity 
      - Non-Hispanic 
      - Hispanic 
 
1,558 
             105  
 
5,328,722 (93.6) 
   365,550 (6.4) 
 
[91.8 – 95.3] 
[4.7 – 8.2] 
Source of payment*** 
      - Private 
      - Medicare 
      - Medicaid 
      - Other† 
 
251 
689 
91 
94 
 
   853,526 (20.2) 
2,690,918 (63.7) 
   327,806 (7.8) 
   350,091 (8.3) 
 
[16.8 – 23.7] 
[59.7 – 67.7] 
[5.9 – 9.6] 
[6.1 – 10.5] 
Patients’ residence†† 
       - Nursing home 
       - Other ††† 
 
50 
575 
 
  168,520 (7.9) 
1,971,606 (92.1) 
 
[4.9 – 10.8] 
[89.2 – 95.0] 
* The numbers represent the mean and the calculated standard deviation. 
** The other race category included Asian, Native Hawaiian/other Pacific Islander, American Indian/Alaska Native, 
and more than one race reported.*** Sources of payment data started to be collected in year 1995. 
† The other source payment category included worker’s compensation, self-pay, and no charge/charity. 
†† Patient residence data started to be collected in year 2001. 
††† The other residence category included private residence, other institution, other residence, and homeless.  
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Patients’ clinical characteristics, diagnostic services, and procedures were available in 
NHAMCS database. Patients who had chest pain in this older adult population were 3.7 million, 
almost 89% of the population. Patients who had a contraindication to beta-blockers were around 
20%: 11% hypotensive, and 15% bradycardic. A summary of patients’ clinical characteristics, 
diagnostic services, and procedures is presented in Table 4.2. 
Table 4.2: Patient Clinical Characteristics 
Clinical Characteristics 
Total population = 6,118,050 
Unweighted 
Frequency    
Weighted 
Frequency (%) 
95% CI of  
the % 
Chest pain  
      - Yes 
      - No 
 
1,055 
123 
 
3,666,299 (88.9) 
457,443 (11.1) 
 
[86.4 – 91.4] 
[8.6 – 13.6] 
Hypotension* 
      - Yes 
      - No             
 
70 
624 
 
252,549 (10.7) 
2,116,200 (89.3) 
 
[7.7 – 13.6] 
[86.4  - 92.3] 
Bradycardia* 
      - Yes 
      - No 
 
107 
587 
 
354,49 (14.9) 
2,014,2527 (85.1)  
 
[11.6 – 18.4] 
[81.6 – 88.4] 
Triage** 
      - High (0-60mins) 
      - Low (>60mins) 
 
1,567 
83 
 
5,341,873 (94.5) 
312,314 (5.5) 
 
[92.9 – 96.0] 
[3.9 – 7.1] 
Cardiac Enzymes test*** 
      - Yes 
      - No 
 
252 
108 
         
        992,945 (68.9) 
448,036 (31.1) 
     
      [62.9 – 74.9] 
      [25.0 – 37.1] 
Cardiac monitor†  
      - Yes 
      - No 
 
791 
374 
 
2,996,405 (68.4) 
1,382,190 (31.6) 
 
[64.5 – 72.4] 
[27.6 – 35.5] 
Electro-cardio-gram  
      - Yes 
      - No 
 
1,582 
189 
 
5,473,217 (89.5) 
644,833 (10.5) 
 
[87.4 – 91.5] 
[8.5 – 12.6] 
Total procedures done†,†† --- 1.16 (±1.65)  [1.1 – 1.2] 
Total diagnostic services 
done † 
 
--- 
 
6.67 (±4.85) 
 
[6.4 – 6.9] 
*Data about blood pressure and heart rate were first collected in 2001. 
**The high triage category represents urgent and emergent cases, the low triage category represent not urgent cases. 
*** Data about cardiac enzyme test was first collected in 2005. 
† Data about cardiac monitor, total procedure done, and diagnostic services done was first collected in 1995. 
†† The numbers represent the mean and the calculated standard deviation. 
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The day and time the patient arrived to the ED, the mode of their arrival, the providers’ 
seen, the type of ward they were admitted to, number of drugs taken, and their discharge status 
were all collected. A majority of patients were admitted on a weekday (almost 70%). Also, a 
majority of patients were seen by an attending physician and a nurse (91% and 90%, 
respectively).  Patients visit characteristics are summarized in Table 4.3.  
Table 4.3: Patient visit characteristics 
Patients’ Visit Characteristics 
Total population = 6,118,050 
Unweighted 
Frequency 
Weighted Frequency 
(%) 
95% CI of the  
% 
Time* 
      - Day (08:00-15:59) 
      - Evening (16:00-23:59) 
      - Night (00:00-7:59) 
 
501 
394 
256 
 
1,817,897 (41.9) 
1,506,112 (34.8) 
1,006,024 (23.2) 
 
[38.2 – 45.8] 
[31.6 – 38.0] 
[20.0 – 26.5] 
Day 
      - Weekday 
      - Weekend 
 
807 
336 
 
2,858,609 (70.4) 
1,199,857 (29.6) 
 
[67.2 – 73.7] 
[26.3 – 32.8] 
Arrival** 
      - Ambulance 
      - Other 
 
252 
238 
 
958,184 (54.8) 
791,567 (45.2) 
 
[48.6 – 60.9] 
[39.1 – 51.4] 
Provider seen*** 
      - Attending physician  
      - Physician assistant 
      - Resident/intern 
      - Nurse practitioner 
      - RN/LPN nurse 
Admission ward† 
      - Critical Care Unit 
      - OR/Cath lab/SDU 
      - Other wards 
 
 1,622 
      42 
308 
23
#
 
1,588 
 
97 
62 
79 
 
5,570,978 (91.1) 
144,812 (2.4) 
889,955 (14.5)                             
66,814 (1.5)                             
5,515,296 (90.1) 
 
              388,635 (40.7) 
           256,438 (26.7) 
 309,764 (32.4)       
 
[89.1 – 93.0] 
                   [1.3 – 3.4] 
               [12.1 – 17.0] 
[0.7 – 2.3] 
               [87.9 – 92.3] 
 
                [32.9 -28.5] 
               [20.0 – 33.7]      
[24.1 – 40.8] 
Discharge status†† 
       - Alive 
       - Dead 
Number of drugs††† 
       - (0-2 drugs) 
       - (3-5 drugs) 
       - (6-8 drugs) 
 
222 
15
# 
 
174 
208 
135 
 
902,868 (95.6) 
41,310 (4.41) 
 
603,248 (32.5) 
754,666 (40.7) 
498,175 (26.8) 
 
 [93.0 – 98.2] 
[1.8 – 6.9] 
 
[26.3 – 38.7] 
[34.6 – 46.7] 
[21.1 – 32.6] 
* Data about time of arrival was first collected in 1995. # It was less than 30 row cases, so not reliable estimates 
** Data about arrival mode was first collected in 2003. 
*** Numbers of providers seen is not mutually exclusive (i.e. a patient can be seen by multiple providers).               
† OR = Operation Room, Cath lab = Catheterization lab, SDU = Step Down Unit, Data about admission was first 
collected in 2005. 
††Data about whether the patient was discharged from any hospital within the last 7 days and data about discharge 
status was first collected in 2005. ††† Data about number of drugs from 2003 to 2010 
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Hospital characteristics are summarized in Table 4.4. Data specific to the ED structure 
(i.e. computerized guideline reminders) were only collected beginning in 2005. Almost 52% of 
the EDs had computerized guideline reminders. 
Table 4.4: Hospital Characteristics 
Hospital Characteristics 
Total population = 6,118,050 
Unweighted 
Frequency 
Weighted Frequency 
(%) 
95% CI of the   % 
Region 
      - Northeast 
      - Midwest 
      - South 
      - West 
 
525 
421 
496 
329 
 
1,507,271 (24.6) 
1,651,986 (27.0) 
1,926,372 (31.5) 
1,032,421(16.9) 
 
[20.5 – 28.8] 
[21.9 – 32.1] 
[26.9 – 35.9] 
[13.8 – 19.9] 
Metropolitan Statistical Area  
      - MSA 
      - Non-MSA 
 
1,455 
316 
 
4,615,904 (75.4) 
1,502,146 (24.6) 
 
[68.2 – 82.7] 
[17.3 – 31.8] 
Hospital Ownership 
      - Voluntary/non-profit 
      - Government/non-federal 
      - Proprietary 
 
1,405 
175 
191 
 
4,751,702 (77.7) 
657,327 (10.7) 
709,021 (11.6) 
 
[74.1 – 81.2] 
[8.2 – 13.3] 
[8.9 – 14.2] 
Guideline reminders* 
       - Yes 
       - No 
 
104 
95 
 
435,149 (52.2) 
398,398 (47.8) 
 
[42.1 – 62.3] 
[37.7 – 57.9] 
* Data about computerized guideline reminders was first collected in 2005. 
 
 
Results by objective 
Objective 1: Trend in use of anti-platelet agents and beta-blockers across 1992-2010 
 
Both anti-platelet agents and beta-blockers showed a positive trend across the years (OR 
= 1.09 [95% CI: 1.07 to 1.19] and OR = 1.16 [95% CI: 1.13 to 1.19], respectively) as shown in 
Figure 4.1. The lowest antiplatelet agent utilization was in 1992 at 13% and highest in 2010 at 
almost 59%. For beta-blockers, the lowest was in 1994 at around 2% and the highest in 2007 at 
38%. There was a gradual increase in the use of both anti-platelet agents and beta-blockers. 
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Figure 4.1: Trend of antiplatelet agents and beta-blockers utilization across the years 
Objective 2: Predictors of anti-platelet agents and beta-blocker use 
 
 Age was a significant predictor of anti-platelet agents use. Younger adults (i.e., <65 years 
old) were more likely to receive an anti-platelet agent than older adults (OR = 1.316 [95% CI: 
1.077 to 1.609]); however, age was not found to be a significant predictor of beta-blocker use. 
Sex, on the other hand, was considered to be a significant predictor of beta-blocker use. Females 
were almost 70% less likely to receive a beta-blocker compared to males (OR = 0.699 [95% CI: 
0.471 to 0.950]). Sex was not considered a significant predictor of antiplatelet agents use. Race 
and ethnicity were not significant predictors for either antiplatelet agents or beta-blockers. 
Patients not living in nursing homes were almost 2.5 times more likely to get antiplatelet agents 
(OR = 2.477 [95% CI: 1.254 to 4.894]); however, there was no significant relationship between a 
patient’s residence and beta-blocker use. The source of payment was not considered to be a 
significant predictor for either antiplatelet agents or beta-blockers use.  
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 Several patient clinical characteristics were significant predictors of medication use.  
Those patients with no chest pain were less likely to get a beta-blocker (OR = 0.330 [95% CI: 
0.132 to 0.827]). Patients with high triage were almost 2.5 times more likely to get an antiplatelet 
agent (OR = 2.483 [95% CI: 1.284 to 4.801]); however, triage did not have a significant 
relationship with beta-blockers use. Interestingly, for every 1 point increase in the number of 
diagnostic services the patients received in the ED, the more likely he/she got an antiplatelet 
agent (OR= 1.145 [95% CI: 1.089 to 1.205]) or a beta-blocker  (OR = 1.074 [95% CI: 1.000 to 
1.153]).  
 Patients who did not arrive in an ambulance were more likely to receive anti-platelet 
agents (OR = 1.652 [95% CI: 1.072 to 2.545]); however, arrival by ambulance was not a 
significant predictor of beta-blocker utilization. The time and day of arrival were not significant 
predictors for either antiplatelet agents or beta-blocker use. Patients who were seen by a nurse 
practitioner were 8% less likely to get an antiplatelet agent (OR = 0.082 [95% CI: 0.022 to 
0.307]). Patients who were treated in a hospital that is located in a Metropolitan Statistical Area 
(MSA) were more likely to get an antiplatelet agent (OR = 1.825 [95% CI: 1.331 to 2.502]). The 
summary of all these bivariate associations are presented in Tables 4.5 and 4.6. 
 After adjusting for demographic characteristics (age, sex, and race) and year, all 
significant predictors of the use of antiplatelet agents remained significant, but for beta-blockers 
only chest pain remained to be a significant predictor of utilization. Results of the multivariate 
analysis are summarized in Tables 4.7 and 4.8. All unadjusted and adjusted analyses are 
summarized in Figure 4.2 and 4.3. 
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Table 4.5: Bivariate associations between patients’ demographic, clinical, visit, and hospital 
characteristics and the use of antiplatelet agents 
Predictor variables Odds ratio (OR) 95% CI of OR 
Demographic 
      - Age (younger than 65 vs. 65 and older) 
      - Sex (females vs. males) 
      - Race (referent: black) 
                  - Other 
                  - White 
      - Ethnicity (Hispanic vs. non-Hispanic)  
      - Payment (referent: Medicaid) 
                  - Other 
                  - Private 
                  - Medicare 
      - Residence (other residence vs. nursing homes) 
 
*1.316  
0.815 
 
0.881 
0.692 
1.184 
 
1.732 
1.364 
0.934 
*2.477  
 
[1.077 - 1.609] 
[0.649 – 1.024] 
 
[0.434 – 1.786] 
[0.461 – 1.038] 
[0.712 – 1.970] 
 
[0.855 – 3.508] 
[0.767 – 2.424] 
[0.542 – 1.611] 
[1.254 – 4.894] 
Clinical 
      - Chest pain (no chest pain vs. chest pain) 
      - Triage (high vs. low) 
      - Total diagnostic services 
Visit 
      - Time (referent: night) 
                     - Day 
                     - Evening 
      - Day (weekend vs. weekday) 
      - Arrival (other transport vs. ambulance) 
      - Provider seen 
                    - Physician (no vs. yes) 
                    - Resident (no vs. yes) 
                    - Nurse RN/LPN (no vs. yes) 
                    - Physician assistant (no vs. yes) 
 
0.792 
*2.483 
*1.145 
 
 
                  0.897 
                  0.943 
                  1.061 
*1.652 
 
0.733 
0.745 
0.693 
1.037 
 
[0.490 – 1.280] 
[1.284 – 4.801] 
[1.089 – 1.205] 
 
 
[0.596 – 1.350] 
[0.628 – 1.413] 
[0.768 – 1.466] 
[1.072 – 2.545] 
 
[0.465 – 1.155] 
[0.507 – 1.093] 
[0.447 – 1.077] 
 [0.412 – 2.606] 
Hospital 
      - Region (referent: West) 
                  - Northeast 
                  - Midwest 
                  - South 
      - MSA (MSA vs. non-MSA) 
      - Ownership (referent: Proprietary) 
                  - Voluntary/non-profit 
                  - Government/non-federal 
 
 
0.842 
0.747 
0.807 
*1.825 
 
1.152 
1.016 
 
 
[0.594 – 1.192] 
[0.538 – 1.038] 
[0.569 – 1.144] 
[1.331 – 2.502] 
 
[0.784 – 1.695] 
[0.565 – 1.827] 
*p<0.05 
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Table 4.6: Bivariate associations between patients’ demographic, clinical, visit, and hospital 
characteristics and use of beta-blockers 
Predictor variables Odds ratio (OR) 95% CI of OR 
Demographic 
      - Age (younger than 65 vs. 65 and older) 
      - Sex (females vs. males) 
      - Race (referent: black) 
                  - Other 
                  - White 
      - Ethnicity (Hispanic vs. non-Hispanic)  
      - Payment (referent: Medicaid) 
                  - Other 
                  - Private 
                  - Medicare 
      - Residence (other residence vs. nursing homes) 
 
1.221 
*0.669 
 
1.269 
0.863 
1.870 
 
0.993 
1.817 
1.344 
1.798 
 
[0.892 – 1.670] 
[0.471 – 0.950] 
 
[0.462 – 3.483] 
[0.517 – 1.442] 
[0.992 – 3.524] 
 
[0.392 – 2.520] 
[0.877 – 3.765] 
[0.702 – 2.575] 
[0.621 – 5.203] 
Clinical 
      - Chest pain (no chest pain vs. chest pain) 
      - Triage (high vs. low) 
      - Total diagnostic services 
Visit 
      - Time (referent: night) 
                     - Day 
                     - Evening 
      - Day (weekend vs. weekday) 
      - Arrival (other transport vs. ambulance) 
      - Provider seen 
                    - Physician (no vs. yes) 
                    - Resident (no vs. yes) 
                    - Nurse RN/LPN (no vs. yes) 
                    - Physician assistant (no vs. yes) 
 
*0.330 
1.604 
*1.074 
 
 
0.860 
1.128 
1.164 
1.384 
 
1.030 
1.014 
1.723 
1.293 
 
[0.132 – 0.827] 
[0.656 – 3.922] 
[1.000 – 1.153] 
 
 
[0.520 – 1.424] 
[0.685 – 1.859] 
 [0.803 – 1.686] 
[0.850 – 2.254] 
 
[0.560 – 1.894] 
[0.612 – 1.682] 
[0.993 – 2.988] 
 [0.457 – 3.653] 
Hospital 
      - Region (referent: West) 
                  - Northeast 
                  - Midwest 
                  - South 
      - MSA (MSA vs. non-MSA) 
      - Ownership (referent: Proprietary) 
                  - Voluntary/non-profit 
                  - Government/non-federal 
 
 
1.248 
0.675 
0.866 
1.555 
 
*2.263 
2.148 
 
 
[0.723 – 2.156] 
[0.361 – 1.263] 
[0.492 – 1.524] 
[0.874 – 2.767] 
 
[1.129 – 4.534] 
[0.945 – 4.882] 
* p<0.05 
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Table 4.7: Multivariate analysis of predictors of antiplatelet agent use* 
Predictor Variables Odds Ratio (OR) 95% CI of OR 
Age (younger than 65 vs. 65 and older) 
Residence (other residence vs. nursing homes) 
Triage (high vs. low)  
Total diagnostic services 
Arrival (other transport vs. ambulance) 
MSA (MSA vs. non-MSA) 
1.261 
2.231 
2.833 
1.136 
1.618 
1.692 
[1.012 – 1.572] 
[1.017 – 4.892] 
[1.329 – 6.038] 
[1.078 – 1.196] 
[1.018 – 2.571] 
 [1.205 – 2.375] 
*adjusted for age, sex, race, and year 
 
Table 4.8: Multivariate analysis of predictors of beta-blocker use* 
Predictor Variables Odds Ratio (OR) 95% CI of OR 
Sex (females vs. males) 
Chest pain (no chest pain vs. chest pain)  
Total diagnostic services 
0.725 
0.339 
1.014 
[0.504 – 1.042] 
[0.131 – 0.880] 
[0.974 – 1.085] 
*adjusted for age, sex, race, and year 
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Sex (Females vs. males) 
Race (Other vs. black) 
Race (White vs. black) 
Age (Younger vs. older 
adults) 
Ethnicity (Hispanic vs. non-
Hispanic)  
Payment (Medicare vs. 
Medicaid) 
Payment (Private vs. 
Medicaid) 
Payment (Other vs. 
Medicaid) 
Residence (other 
residence vs. nursing 
homes) 
Chest pain (no chest pain 
vs. chest pain) 
Triage (high vs. low) 
Total diagnostic services 
Time (Day vs. night) 
Time (Evening vs. night) 
Day (weekend vs. 
weekday) 
Arrival (other transport vs. 
ambulance) 
Physician (no vs. yes) 
Resident (no vs. yes) 
Nurse RN/LPN (no vs. yes) 
Nurse practitioner (no vs. 
yes) 
Physician assistant (no vs. 
yes) 
Region (Northeast vs. 
West) 
Region (Midwest vs. West) 
Region (South vs. West) 
MSA (MSA vs. non-MSA) 
Ownership (Voluntary vs. 
Proprietary) 
Ownership (Government 
vs. Proprietary) 
Age (younger than 65 vs. 65 
and older) "Adjusted" 
Residence (other residence vs. 
nursing homes) "Adjusted" 
Triage (high vs. low) 
"Adjusted" 
Total diagnostic services 
"Adjusted" 
Arrival (other transport vs. 
ambulance) "Adjusted" 
MSA (MSA vs. non-MSA) 
"Adjusted" 
0 0.5 1 1.5 2 2.5 3 3.5 4 4.5 5 5.5
Less likely to receive anti-platelets More likely to receive anti-platelets 
Figure 4.2: Forest plot of bivariate associations between predictors and anti-platelets use 
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Sex (Females vs. males) 
Race (Other vs. black) 
Race (White vs. black) 
Age (Younger vs. older 
adults) 
Ethnicity (Hispanic vs. non-
Hispanic)  
Payment (Medicare vs. 
Medicaid) 
Payment (Private vs. 
Medicaid) 
Payment (Other vs. 
Medicaid) 
Residence (other 
residence vs. nursing 
homes) 
Chest pain (no chest pain 
vs. chest pain) 
Triage (high vs. low) 
Total diagnostic services 
Time (Day vs. night) 
Time (Evening vs. night) 
Day (weekend vs. 
weekday) 
Arrival (other transport vs. 
ambulance) 
Physician (no vs. yes) 
Resident (no vs. yes) 
Nurse RN/LPN (no vs. yes) 
Nurse practitioner (no vs. 
yes) 
Physician assistant (no vs. 
yes) 
Region (Northeast vs. 
West) 
Region (Midwest vs. West) 
Region (South vs. West) 
MSA (MSA vs. non-MSA) 
Ownership (Voluntary vs. 
Proprietary) 
Ownership (Government 
vs. Proprietary) 
Sex (females vs. males) 
"Adjusted" 
Chest pain (no chest pain 
vs. chest pain) "Adjusted" 
Total diagnostic services 
"Adjusted" 
0 0.5 1 1.5 2 2.5 3 3.5 4 4.5 5 5.5
Less likely to receive beta-blockers More likely to receive beta-blockers 
 
Figure 4.3: Forest plot of bivariate associations between predictors of beta-blocker use 
 
         Adjusted         Unadjusted 
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Objective 3: The effect of the use of anti-platelet agents and beta-blockers on in-hospital 
mortality and length of hospital stay 
 
 In-hospital mortality in this population was around 4%. After a chi-square test between 
the utilization of antiplatelet agents and beta-blockers and in-hospital mortality, there was no 
significant difference between patients receiving anti-platelet agents and patients who did not in 
their in-hospital mortality (χ2 = 0.008, p= 0.909). However, there was a significant difference 
between patients receiving beta-blockers and patients who did not in their in-hospital mortality 
(χ2 = 2.518, p= 0.041). 
 The mean length of hospital stay was 6.6 (±8.2) days.  A linear regression between the 
utilization of antiplatelet agents and beta-blockers and length of hospital stay indicated that there 
was no statistically significant relationship between antiplatelet agents and beta-blockers use and 
length of hospital stay (β = 0.937, p = 0.411) and (β = -0.045, p = 0.967) respectively. 
 
Objective 4: The effect of ED guideline reminders on the use of anti-platelet agents and beta-
blockers 
  
 Almost 52% hospitals had computerized guideline reminders. A bivariate logistic 
regression showed that patients who were treated in EDs that had a computerized guideline 
reminder were twice as likely to get an antiplatelet agent (OR = 2.004 [95% CI: 1.052 to 3.815]).  
Computerized reminders were not significantly associated with beta-blocker use (OR = 0.594 
[95% CI: 0.304 to 1.162]). 
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CHAPTER 5 
 
Discussion 
 
Discussion of descriptive results 
 
The representation of females in our study is highly consistent with the literature.
1,2
 We 
found that the older the age group the higher percentage of females (χ2= 104.5, p < 0.001).  It has 
been suggested that women present with AMI at older ages.
1
 The percentage of patients who 
were admitted from a nursing home in our population was around 7.9%, which is similar to the 
proportion of nursing home residents in other studies (6.4%).
3
 
 Chest pain is the hallmark symptom of AMI. In our study almost 89% of our patients 
experienced chest pain. This was consistent with the older adult literature.
1,2 
However, when 
dividing older adults into different age groups, we found that the older the age group, the less 
likely they were to experience chest pain (younger adults (55-64 years) was 90% and older old 
adults (≥85 years) was 78%, χ2 = 15.54, p = 0.045). This was also found in other studies that 
looked at the differences by age in AMI presentation.
2,4  
Less than 20% of our patients had a contraindication to beta-blockers. Approximately 
11% had bradycardia and almost 15% had hypotension, some patients had both hypotension and 
bradycardia. These percentages were similar to a study that looked at the percentage of patients 
who had a contraindication to beta-blockers.
5 
 
In our study, about 70% of the patients visited the ED during the day or evening shift. 
This is consistent with other studies where the percentage of patients who arrived during the day 
and evening shift was 69-74% and during the night shift was 26-32%.
1,6 
Almost half of our 
patients  arrived by an ambulance, which is also similar to the previous study (45%).
1 
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Discussion of results by objective 
Objective 1: Trend in use of anti-platelet agents and beta-blockers across 1992-2010 
 
 This study showed a positive trend in both antiplatelet agents and beta-blockers use. This 
also was seen in another study.
7 
One study found that administration of aspirin and beta-blockers 
within the first 24 hours of admission showed a positive trend from years 1990 to 2006.
7 
Another 
study that looked at in-hospital use of aspirin and beta-blockers from years 1992 to 2002 also 
found a significant positive increase in both treatments over time.
8
 
In our study, underuse of both antiplatelet agents and beta-blockers in the ED is evident. 
Our utilization percentages are hard to compare with other studies in the literature, because most 
of the studies reported in-patient utilization rates.
2,9,10 
Interestingly, even among the studies that 
intended to look only at ED care, their definition of acute care was the receipt of medication 
within the first 24 hours of admission, which actually may have been in the ED or in the in-
patient setting.
1,4
 
This study showed that beta-blockers were highly underused in the ED (overall use = 
14%). This underuse may be attributed to the fact that beta-blockers are more often administered 
once the patient is admitted to the hospital. Because beta-blockers have a long list of 
contraindications that the physician has to check before administration, early use may be hard to 
accomplish given the time constraints in the ED.
5
 Furthermore, whether some of these are 
absolute or relative contraindications may be unclear to the physicians, such as non-acute 
asthma, COPD, and chronic heart failure.
5  
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The strong drop in beta-blockers use noticed in our study, from 32% in 2009 to 10% in 
2010, may be explained by the 2008 changes in ACC/AHA performance measures that omitted 
the recommendation of administering beta-blockers at arrival.
11 
This change was likely a result 
of findings from the COMMIT trial, which found that intravenous beta-blockers administered at 
arrival may cause cardiogenic shock for patients with history of heart failure.
12
 The ACC/AHA 
guidelines still consider beta-blockers to be class I indication for many patients.
11
 Oral beta-
blockers are still useful and effective for a wide range of patients,
13
 but it was omitted from the 
AMI performance measures because of safety concerns.
11
 This change was widely adopted by 
hospitals because this measure was also removed from the AMI measures list common to the 
Centers for Medicare & Medicaid Services (CMS) and The Joint Commission in March 2009.
14 
This wide adoption may be explained by the fact that, If a hospital does not comply to 
JCAHO/CMS, it will lose 2.0 percent of their annual market basket update, only hospitals who 
are enrolled in the inpatient prospective payment system (IPPS).
14 
Objective 2: Predictors of anti-platelet agents and beta-blocker use 
 
Age 
 There is overwhelming evidence for the underuse of effective AMI treatments in the 
older adult population.
4,7
 Our study supported these previous findings since we found older 
adults were less likely to receive an antiplatelet agent; however, no significant relationship was 
found with beta-blockers. The older adult population is known to have more contraindications to 
medications than their counterparts due to their increased comorbidities. For example, 
gastrointestinal bleeding is a common problem in older adults that may prevent the 
administration of an antiplatelet agent. A previous study found a 15% reduction in the likelihood 
of getting aspirin and 21% with beta-blockers, respectively for every 10-year increase in age.
4 
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The TIMI III Registry study found that older adults were less likely to receive aspirin and beta-
blockers (p = 0.04).
15 
This was also confirmed by GRACE global registry, which found that the 
older the age group the less likely was the utilization of aspirin and beta-blockers.
10 
Another 
study found that one of the strongest determinants against receiving a beta-blocker was age older 
than 65 years.
16 
Moreover, a study using NRMI database found that older adults (>75) were 
consistently less likely to receive beta-blockers within 24 hours of admission across the years 
1990 to 2006.
7 
Sex 
 There is contradicting evidence about the effect of patient’s sex on the receipt of AMI 
treatment. Our study found that females were less likely to receive a beta-blocker in the bivariate 
logistic regression analysis; however, after adjusting for age, sex, race, and year, the relationship 
did not remain significant, also there was no significant relationship with antiplatelet agents. One 
study found that the relationship between sex and AMI treatment was not significant after 
adjusting for age.
1 
They suggested that women were less likely to receive AMI treatment just 
because they were generally older at presentation with AMI.
1 
Several other studies found that 
women were consistently older than men when presenting with AMI, and they presented with 
atypical symptoms of AMI, like no chest pain, that may also explain the lower use of evidenced 
based drugs in females.
1,17-23 
Four studies using the largest databases of AMI (NRMI, 
CRUSADE, TIMI, and CCP) found that women were less likely to receive aspirin and beta-
blockers.
7,23-25 
Another study found that one of the strongest determinants against receiving a 
beta-blocker is female gender.
16 
Furthermore, a study using the NRMI database found that 
females were consistently less likely to receive beta-blockers within 24 hours of admission 
across the years 1990 to 2006.
7  
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Race and ethnicity 
 In our study we found that race and ethnicity were not associated with receipt of both 
antiplatelet agents and beta-blockers. This was consistent with other studies that also found no 
significant relationships between race and ethnicity and AMI treatment.
26-28 
However, in the 
TIMI registry, they found that blacks were less likely to get beta-blockers, but there was no 
significant relationship with aspirin.
15 
In a Medicare study, they found that white people are more 
likely to get early beta-blockers (OR, 1.14; 95% CI, 1.04 to 1.23).
13 
Interestingly, a study using 
the NRMI database found that blacks were less likely to receive beta-blockers within 24 hours of 
admission in the earlier years of the study (1994-1996) but in the later years (2003-2006) they 
were more likely to get beta-blockers.
7 
Payment 
 There was no significant relationship between the source of payment and receipt of 
antiplatelet agents and beta-blockers. This result was expected because more than 60% of our 
patients were covered by Medicare, so it is hard to find the effect of payment in this kind of 
distribution. Plus, there could be a spill-over effect from the Medicare patients on the other 
patients especially that Medicare emphasizes a lot on quality. A previous study looked at the 
relationship between source of payment and AMI care, but it only looked at private payment by 
differentiating between patients who had an HMO plan and FFS plan. The authors found that 
patients with HMO plans were more likely to receive aspirin and beta-blockers comparing to 
patients with FFS plan.
29
 
Residence 
 In our study, patients admitted from nursing homes were less likely to be administered an 
antiplatelet agent. This may be attributed to the possibility that nursing home residents may be 
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given aspirin by the nursing home staff when AMI is expected (i.e. experiencing chest pain). 
This was confirmed by another study, which found that getting aspirin and being admitted from a 
nursing home is negatively correlated (Rho = -0.069 (p < 0.001)).
3 
Chest pain 
 In our study, patients who did not have chest pain were less likely to receive beta-
blockers, but there was no significant association between antiplatelet agents and chest pain. This 
is similar to another study which found that people who experienced chest pain within < 48 hours 
of admission were more likely to get beta-blockers (OR, 1.71; 95% CI, 1.58 to 1.84).
13
 Another 
study found that patients who experienced chest pain are more likely to get aspirin.
25
  
Hospital Region, Ownership, and MSA 
 Our study found no significant relationship between hospital region and receipt of 
antiplatelet agents or beta-blockers. Some previous studies have found that hospitals in the 
Northeast region did better on various AMI performance measures.
6,30
 
Objective 3: The effect of the use of anti-platelet agents and beta-blockers on in-hospital 
mortality and length of hospital stay 
In-hospital mortality 
 Our study found that there was a significant difference in the in-hospital mortality rate 
between patients who received beta-blockers and patients who did not. The majority of patients 
who took a beta-blocker lived (99%). However, there was no significant difference in the in-
hospital mortality rate between patients who received an antiplatelet agent and patients who did 
not. At 4%, in-hospital mortality in our population was very similar to other studies that looked 
at AMI in-hospital mortality (4-7%).
16,31-35 
The 4% in our study only represents 15 actual cases 
of AMI mortality, hence it is not necessarily comparable to the 4% in other studies. We also 
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noticed that older age groups in our population had higher in-hospital mortality than the younger 
age groups, but it was not significantly different. Other studies found this relationship to be 
significant, the older the age group the higher the in-hospital mortality rate.
10,32-34
 Similar to our 
findings, three studies found that beta-blockers were associated significantly with lower in-
hospital mortality rates.
16,31,35 
Another study found that the early use of guideline-recommended 
therapies (aspirin, beta-blockers, glycoprotein IIb/IIIa inhibitors, heparin, and catheterization) 
were associated with lower in-hospital mortality rates.
34
 
Length of hospital stay 
 Mean LOS was 6.6 (±8.2) days. It was similar to other studies who had hospitalized older 
adults with AMI.
36 
We did not find a significant relationship between receipt of antiplatelet 
agents or beta-blockers and length of hospital stay. It may be expected that medical treatment 
(i.e. antiplatelet agents and beta-blockers) may not have a significant effect on LOS like 
interventional treatments may have (e.g. PCI, CABG, and fibrinolysis). Krumholz et al. found 
that patients who received aspirin had a shorter LOS than patients who did not; however, it was 
not mentioned if they were significantly different or not.
25 
 
Objective 4: The effect of ED guideline reminders on the use of anti-platelet agents and beta-
blockers 
Almost 52% of hospitals had computerized guideline reminders. A bivariate logistic 
regression showed that patients who were treated in EDs that had a computerized guideline 
reminder were twice as likely to get an antiplatelet agent, but it was not significantly associated 
with beta-blockers use. As mentioned before, beta-blockers are harder to administer in an ED 
setting, so it is not expected that ED reminders may increase their use in the ED. Plus, aspirin 
could be prescribed by a nurse or a physician in the ED, unlike beta-blockers which are only 
76 
 
prescribed by a physician. We cannot compare our results to other studies, since no studies to our 
knowledge examined the effect of computerized clinical decision support (CCDS) systems in the 
ED on AMI treatment. However, several studies have looked at the effect of CCDS in other 
disease states and in different settings.
37-40 
Few studies have examined the effect of CCDS 
system in the ED.
41-42  
One study used the CCDS system in the ED to screen for HIV. They 
found that using the CCDS for this purpose increased the detection rate of HIV and hence helped 
in treating undetected HIV cases.
41 
The other study found that when incorporating pneumococcal 
vaccination reminders in the CCDS system in the ED, it helped to overcome existing barriers that 
the health professionals had towards pneumococcal vaccination.
42
 
Limitations 
 The lack of detailed clinical information in the database prevents us from excluding 
ineligible subjects for drug therapy, which is especially important for beta-blockers. Only blood 
pressure and heart rate were available for us to identify patients who were hypotensive or 
bradycardic, which is considered a contraindication to beta-blockers administration.  Also, 
because of the lack of data on out-of-hospital management, we were unable to determine if 
patients received therapy before hospital arrival. This is more relevant with respect to aspirin, as 
it may be given in the ambulance or taken at home by the patient. Both of these 
misclassifications may have overestimated the percentage of underuse in our study.  
If the database shows that a patient was prescribed a drug that does not necessarily mean 
that the patient has actually taken the drug. Even when a drug is mentioned to be given in the 
emergency department, it does not necessarily mean that the patient was administered the drug. 
In our case, there is little that we can do to overcome that, because there is no other way that we 
77 
 
could find this information other than the emergency department form.  We can only 
acknowledge this as a limitation, which is common in most database research. 
A researcher is limited by the information collected. It is important to have in mind that 
the database is not specifically built to answer the research question. Hence, not all the 
information needed to carry out the research maybe available. Sometimes the incompleteness of 
data would be a minor issue that can be acknowledged, but sometimes it is a major issue that 
may cause us to reconsider using this data source. For example, we are limited by the number of 
drugs available in each visit record in NHAMCS. From 2003 to 2010, there are 8 drugs 
available, from 1995 to 2002, there are 6 drugs available, and from 1992 to 1994, there are 5 
drugs available. This may cause us to miss some of the utilization of anti-platelet agents and 
beta-blockers, especially in patients with a lot of comorbidities, which may likely receive a large 
number of drugs. Another important matter to note here that from year 1992 to 1996 the variable 
indicating whether the diagnosis is probable or not was not available. These years had larger 
numbers of participants, meaning it is probable that some of these cases did not have a confirmed 
AMI diagnosis. We chose to add these years because of our need to meet sample size 
requirements for national estimates and acknowledge it as a limitation. 
In our study, there was some important information that was not available in order to 
describe the population better. For example, the patient’s medical history was not available. If a 
patient had a previous AMI in a different setting, which is considered a cardiac risk factor, we 
were unable to account for it. Also, a patient’s drug history is not available, so previous usage of 
anti-platelets or beta-blockers will not be known. This is important because it could affect the ED 
use for these drugs. Furthermore, the patient’s social history, such as smoking status, is not 
available, which is also considered to be a cardiac risk factor. Furthermore, sociodemographic 
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patient factors are not available such as education, income, primary language spoken, and 
employment. Having this information better describes our population, and their risks to 
outcomes. 
Data may be subject to many types of inaccuracies. There could be miscoding practices, 
either deliberately or just by human error. In our database it is more likely to be human error than 
deliberate miscoding. Since NHAMCS does not represent administrative claims data and there is 
no incentive to deliberately miscode the diagnosis or procedures to get higher reimbursements, 
this would be highly unlikely. Diagnosis codes are the only way to identify our population, to 
confirm our diagnosis; only visits with unquestionable diagnosis were used. Some studies can 
confirm the diagnosis by available clinical information, but in our case it was not possible.   
Some limitations arise from our relatively small sample size. We were not able to control 
for all available covariates in our multivariate regression analysis. Hence, we only controlled for 
important demographic variables, such as age, sex, and race. We were also not able to carry out a 
Kaplan-Meir survival analysis to examine in-hospital mortality or a logistic regression analysis, 
because we only had 15 cases of mortality across 2005-2010.  
 
Practical implications 
 Delivering time-sensitive therapies in the ED should be a priority by the hospital staff; 
this may be facilitated by forming a system that ensures receipt of these therapies before the 
patient is discharged from the ED.
43 
Having ED clinical pathways and protocols that promote use 
of guideline-recommended therapies in the ED is a good approach to ensuring receipt of 
antiplatelet agents. These clinical pathways and protocols may be incorporated in a CCDS to 
increase their efficiency. Also, it is important to maximize the provision of these effective 
medications to AMI patients, irrespective of age and sex.
1 
When emergency physicians work 
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together with other health care providers (e.g., cardiologists and EMS) this will facilitate a better 
provision of care in the ED to AMI patients.
6 
Also, this is an area where ED pharmacists could 
best help in, improving the provision of guideline-concordant treatment to older AMI patients 
presenting to the ED. A recent literature review have shown that pharmacists have a great role in 
the ED in increasing medication safety and improving patient drug reconciliation.
44
 
Future Directions 
 Research about the care given in the ED setting needs more attention. It is important to 
look at other guideline-recommended therapies that should be given in the ED, like fibrinolysis 
and PCI in the older adult population. Conducting a study to be at the ED-level could give 
another perspective on ED care. Another acute care setting that needs attention is the EMS. More 
studies are needed to quantify the actual use of aspirin in EMS, plus other care guidelines like, 
12-led-ECG and fibrinolysis in the ambulance. Furthermore, clinical guidelines should create 
and validate performance measures that are ED-specific and that merit more research.
37  
Also, 
there are other structure components that are not collected in NHAMCS that may be looked at in 
future research, like the effect of being treated with a cardiologist in the ED. 
Conclusion 
This is the first study to capture this long period of time of ED AMI care for older adults. 
It provided national estimates about older adults ED use of antiplatelet agents and beta-blockers 
from 1992 to 2010, which showed that both had a positive trend in utilization across the years. 
This study confirms the finding that older adults and females have lower utilization rates of AMI 
treatment than their counterparts. This study also reveals new relevant associations, like the 
effect of chest pain and triage on utilization rates of antiplatelet agents and beta-blockers. This 
study attempted to evaluate the impact of having a computerized reminder to prompt ED staff to 
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use guidelines, on the usage of antiplatelet agent therapy in the ED. Our results showed that 
having a computerized guideline reminder increase the utilization of antiplatelet agents but not 
beta-blockers. This study also attempted to see the effect of ED utilization of antiplatelet agents 
and beta-blockers on hospital outcomes, like in-hospital mortality and LOS. We only found that 
beta-blockers were significantly associated with lower in-hospital mortality. Finally, this study 
may help in increasing the awareness of the ED health care professionals of older adults AMI 
care. 
  
81 
 
References 
 
1. Vinson D, Magid D, Brand D, Masoudi F, Ho M, Lyons E, et al. Patient sex and quality of ED 
care for patients with myocardial infarction. Am J Emerg Med. 2007;25:996-1003. 
2. Mehta R, Rathore S, Radford M, Wang Y, Wang Y, Krumholz H. Acute myocardial infarction 
in the elderly: differences by age. J Am Coll Cardiol. 2001;38:736–41. 
3. Radcliff T and Levy C. Examining Guideline-concordant care for acute myocardial infarction 
(AMI): the case of hospitalized post-acute and long-term care (PAC/LTC) residents. Journal of 
hospital medicine. 2010;5:E3-E10. 
4. Magid DJ, Masoudi FA, Vinson DR, van der Vlugt TM, Padgett TG, Tricomi AJ, Lyons EE, 
Crounse L, Brand DW, Go AS, Ho PM, Rumsfeld JS. Older emergency department patients with 
acute myocardial infarction receive lower quality of care than younger patients. Ann Emerg Med. 
2005 Jul;46(1):14-21. 
5. Vega DD, Dolan KL, Pollack ML. Beta-blocker use in elderly ED patients with acute 
myocardial infarction. Am J Emerg Med. 2006 Jul;24(4):435-9. 
6. Tsai C, Magid D, Sullivan A, Gordon J, Kaushal R, Ho M, et al. Quality of care for acute 
myocardial infarction in 58 U.S. emergency departments. Emerg Med. 2010;17: 940-50. 
7. Peterson E, Shah B, Parson L, Pollack C, French W, et al. Trends in quality of care for patients 
with acute myocardial infarction in the National Registry of Myocardial Infarction from 1990 to 
2006. Am Heart J. 2008;156:1045-55. 
8. Gottlieb S, Behar S, Hod H, Zahger D, Leor J, Hasdai D, Hammerman H, Wagner S, Sandach 
A, Schwartz R, Green MS, Adunsky A, Intensive Cardiac Care Working Group of the Israel 
Heart Society. Trends in management, hospital and long-term outcomes of elderly patients with 
acute myocardial infarction. Am J Med. 2007 Jan;120(1):90-7. 
9. Rathore SS, Mehta RH, Wang Y, Radford MJ, Krumholz HM. Effects of age on the quality of 
care provided to older patients with acute myocardial infarction. Am J Med. 2003;114(4):307-15. 
10. Avezum A, Makdisse M, Spencer F, Gore JM, Fox KA, Montalescot G, Eagle KA, White K, 
Mehta RH, Knobel E, Collet JP, GRACE Investigators. Impact of age on management and 
outcome of acute coronary syndrome: observations from the Global Registry of Acute Coronary 
Events (GRACE). Am Heart J. 2005;149(1):67-73. 
11. Krumholz HM, Anderson JL, Bachelder BL, et al. ACC/AHA 2008 performance measures 
for adults with st-elevation and non–st-elevation myocardial infarction: a report of the American 
College of Cardiology/American Heart Association task force on performance measures (writing 
82 
 
committee to develop performance measures for st-elevation and non–st-elevation myocardial 
infarction). JACC. 2008;52(24):2046-99. 
12. Wissenschaftlicher Beirat Group. COMMIT (Clopidogrel and Metoprolol Infarction Trial). 
Internist. 2006;47:764–766. 
 13. Krumholz H, Radford M, Wang Y, Chen J, Marciniak T. Early β-blockers therapy for acute 
myocardial infarction in elderly patients. Ann Intern Med. 1999;131:648-654. 
14. Change in Composition of the National Hospital Quality Acute Myocardial Infarction Set 
Document. Health Services Advisory Group Website. http://www.hsag.com/ 
App_Resources/Documents/AMI-6_Retirement_Jan09.pdf. Accessed March 26,2012. 
15. Stone PH, Thompson B, Anderson HV, Kronenberg MW, Gibson RS, Rogers WJ, Diver DJ, 
Théroux P, Warnica JW, Nasmith JB, Kells C, Kleiman N, McCabe CH, Schactman M, 
Knatterud GL, Braunwald E. Influence of race, sex, and age on management of unstable angina 
and non-Q-wave myocardial infarction: The TIMI III registry. JAMA. 1996 Apr 
10;275(14):1104-12. 
16. Wienbergen H, Zeymer U, Kai A, Juenger C, Schiele R, Heer T, et al. Prognostic impact of 
acute beta-blocker therapy on top of aspirin and angiotensin-converting enzyme inhibitor therapy 
in consecutive patients with ST-elevation acute myocardial infarction. Am J Cardiol. 
2007;99:1208-1211. 
17.  Jelinski SE, Ghali WA, Parsons GA, et al. Absence of sex differences in pharmacotherapy 
for acute myocardial infarction. Can J Cardiol. 2004;20:899- 905. 
18. Heer T, Schiele R, Schneider S, et al. Gender differences in acute myocardial infarction in 
the era of reperfusion (the MITRA registry). Am J Cardiol. 2002;89:511-7. 
19. Mahon NG, McKenna CJ, Codd MB, et al. Gender differences in the management and 
outcome of acute myocardial infarction in unselected patients in the thrombolytic era. Am J 
Cardiol. 2000;85:921-6. 
20.  Hanratty B, Lawlor DA, Robinson MB, et al. Sex differences in risk factors, treatment and 
mortality after acute myocardial infarction: an observational study. J Epidemiol Community 
Health. 2000;54:912-6. 
21. Oka RK, Fortmann SP, Varady AN. Differences in treatment of acute myocardial infarction 
by sex, age, and other factors (the Stanford Five-City Project). Am J Cardiol. 1996;78:861-5. 
22. Clarke KW, Gray D, Keating NA, et al. Do women with acute myocardial infarction receive 
the same treatment as men? BMJ. 1994;309:563-6. 
 23. Blomkalns AL, Chen AY, Hochman JS, et al. Gender disparities in the diagnosis and 
treatment of non–ST-segment elevation acute coronary syndromes. J Am Coll Cardiol . 
2005;45:832-7. 
83 
 
 24. Vaccarino V, Rathore SS,Wenger N, et al. Sex and racial differences in the management of 
acute myocardial infarction, 1994 through 2002. N Engl J Med. 2005;353:671-82.  
25. Krumholz HM, Radford MJ, Ellerbeck EF, Hennen J, Meehan TP, Petrillo M, Wang Y, 
Kresowik TF, Jencks SF. Aspirin in the treatment of acute myocardial infarction in elderly 
Medicare beneficiaries Patterns of use and outcomes. Circulation. 1995 Nov 15;92(10):2841-7. 
 26. Takakuwa KM, Shofer FS, Hollander JE. Aspirin administration in ED patients who 
presented with undifferentiated chest pain: age, race, and sex effects. Am J Emerg Med. 2010 
Mar;28(3):318-24. 
 27. Sonel AF, Good CB, Mulgund J, et al. Racial variations in treatment and outcomes of black 
and white patients with high-risk non–STelevation acute coronary syndromes: insights from 
CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse 
Outcomes With Early Implementation of the ACC/AHA Guidelines?). Circulation. 
2005;111:1225-32. 
 28.  Mehta RH, Marks D, Califf RM, Sohn S, Pieper KS, Van de Werf F, Peterson ED, Ohman 
EM, White HD, Topol EJ, Granger CB. Differences in the clinical features and outcomes in 
African Americans and whites with myocardial infarction. Am J Med. 2006 Jan;119(1):70.e1-8. 
29.  Soumerai SB, McLaughlin TJ, Gurwitz JH, Pearson S, Christiansen CL, Borbas C, Morris 
N, McLaughlin B, Gao X, Ross-Degnan D. Timeliness and quality of care for elderly patients 
with acute myocardial infarction under health maintenance organization vs fee-for-service 
insurance. Arch Intern Med. 1999 Sep 27;159(17):2013-20. 
30.  Jencks SF, Cuerdon T, Burwen DR, et al. Quality of medical care delivered to Medicare 
beneficiaries: a profile at state and national levels. JAMA. 2000;284:1670–6. 
31. Medina HM, Cannon CP, Zhao X, et al. Quality of acute myocardial infarction care and 
outcomes in 33,997 patients aged 80 years or older: Findings from Get With The Guidelines-
Coronary Artery Disease (GWTG-CAD). Am Heart J. 2011;162:283-290. 
32. Peterson ED, Shah BR, Parsons L, et al. Trends in quality of care for patients with acute 
myocardial infarction in the National Registry of Myocardial Infarction from 1990 to 2006. Am 
Heart J. 2008;156(6):1045-55. 
33. Yan RT, Yan AT, Tan M, et al, Canadian Acute Coronary Syndromes (ACS) Registry 
Investigators. Age-related differences in the management and outcome of patients with acute 
coronary syndromes. Am Heart J. 2006;151(2):352-9. 
34. Alexander KP, Roe MT, Chen AY, et al. Evolution in cardiovascular care for elderly patients 
with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE National 
Quality Improvement Initiative. J Am Coll Cardiol. 2005;46(8):1479-87. 
35. Krumholz H, Radford M, Wang Y, Chen J, Marciniak T. Early β-blockers therapy for acute 
myocardial infarction in elderly patients. Ann Intern Med. 1999;131:648-654. 
84 
 
36. Stern S, Behar S, Leor J, Harpaz D, Boyko V, Gottlieb S, Israeli Working Group on Intensive 
Cardiac Care, Israel Heart Society. Presenting symptoms, admission electrocardiogram, 
management, and prognosis in acute coronary syndromes: differences by age. Am J Geriatr 
Cardiol. 2004 Jul-Aug;13(4):188-96. 
37. Nilasena DS, Lincoln MJ. A Computer-Generated Reminder System Improves Physician 
Compliance with Diabetes Preventive Care Guidelines. Proc Annu Symp Comput Appl Med 
Care. 1995:640–645. 
38. Trivedi MH, Daly EJ, Kern JK, Grannemann BD, Sunderajan P, Claassen CA. Barriers to 
implementation of a computerized decision support system for depression: an observational 
report on lessons learned in "real world" clinical settings. BMC Medical Informatics and 
Decision Making. 2009;9:6. 
39. Haynes RB, Wilczynski NL. Effects of computerized clinical decision support systems on 
practitioner performance and patient outcomes: Methods of a decision-maker-researcher 
partnership systematic review. Implementation Science. 2010;5:12. 
40. Damiani G, Pinnarelli L, Colosimo SC, et al. The effectiveness of computerized clinical 
guidelines in the process of care: a systematic review. BMC Health Services Research. 
2010;10:2. 
41. Wilbur L, Huffman G, Lofton S, Finnell JT. The Use of a Computer Reminder System in an 
Emergency Department Universal HIV Screening Program. Ann Emerg Med. 2011;58:S71-S73. 
42. Dexheimer JW, Jones I, Chen Q, Talbot TR, Mason D, Aronsky D. Providers’ Beliefs, 
Attitudes, and Behaviors before Implementing a Computerized Pneumococcal Vaccination 
Reminder. Academic Emergency Medicine. 2006;13:1312–1318. 
43. Pham J, Kelen G, Pronovost P. National study on the quality of emergency department care 
in the treatment of acute myocardial infarction and pneumonia. Acad Emerg Med. 
2007;14:10:856-63. 
44. Cohen V, Jellinek SP, Hatch A, Motov S. Effect of clinical pharmacists on care in the 
emergency department: A systematic review. Am J Health-Syst Pharm. 2009;66:1353-61. 
 
 
 
 
 
85 
 
APPENDIX A 
 
SAS code 
 
SAS code of data manipulation (example of year 2010) 
/*work program for year 2010*/ 
data nhamcs.nhamcs10work; 
set nhamcs.nhamcs10; 
 
if substr(DIAG1,1,3) = '410' then AMI1adm = 1; 
else AMI1adm = 0; 
 
if substr(DIAG2,1,3) = '410' then AMI2adm = 1; 
else AMI2adm = 0; 
 
if substr(DIAG3,1,3) = '410' then AMI3adm = 1; 
else AMI3adm = 0; 
 
if AMI1adm = 1 and prdiag1 = 0 then participant1 = 1; 
else participant1 = 0; 
 
if AMI2adm = 1 and prdiag2 = 0 then participant2 = 1; 
else participant2 = 0; 
 
if AMI3adm = 1 and prdiag3 = 0 then participant3 = 1; 
else participant3 = 0; 
 
if seen72 = 1 then seen = 1; 
else seen = 0; 
 
if AGE>=55 then older =1; 
else older=0; 
 
if (participant1 = 1 or participant2 = 1 or participant3= 1) and older = 1 
and seen= 0 then participant = 1; 
else participant= 0; 
 
if age >=55 then agecat = 3; 
if age >=65 then agecat = 2; 
if age >=75 then agecat = 1; 
if age >=85 then agecat = 0; 
 
if substr(HDDIAG,1,3) = '410' then AMIdisch = 1; 
else AMIdisch = 0; 
 
antiplatelet = 0; 
if drugid1 = '' and drugid2 = '' and drugid3 = '' and drugid4 ='' and drugid5 
='' and drugid6 ='' and drugid7 = '' and drugid8 = '' then antiplatelet = .; 
if drugid1 = 'd04258' or 'd00514' or 'd00213' or drugid2 = 'd04258' or 
'd00514' or 'd00213' or drugid3 = 'd04258' or 'd00514' or 'd00213' or drugid4 
= 'd04258' or 'd00514' or 'd00213' or drugid5 = 'd04258' or 'd00514' or 
'd00213' or drugid6 = 'd04258' or 'd00514' or 'd00213' or drugid7 = 'd04258' 
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or 'd00514' or 'd00213' or drugid8 = 'd04258' or 'd00514' or 'd00213' then 
antiplatelet= 1; 
 
aspirin = 0; 
if drugid1 = '' and drugid2 = '' and drugid3 = '' and drugid4 ='' and drugid5 
='' and drugid6 ='' and drugid7 = '' and drugid8 = '' then aspirin = .; 
if drugid1 = 'd00170' or drugid2 = 'd00170' or drugid3 = 'd00170' or drugid4 
= 'd00170' or drugid5 = 'd00170' or drugid6 = 'd00170' or drugid7 = 'd00170' 
or drugid8 = 'd00170' then aspirin= 1; 
 
betablocker = 0; 
if drugid1 = '' and drugid2 = '' and drugid3 = '' and drugid4 ='' and drugid5 
='' and drugid6 ='' and drugid7 = '' and drugid8 = '' then betablocker = .; 
if drugid1 = 'd00134' or 'd00004' or 'd03847' or 'd00709' or 'd00128' or 
'd00018' or 'd00176' or 'd05265' or 'd00032' or drugid2 = 'd00134' or 
'd00004' or 'd03847' or 'd00709' or 'd00128' or 'd00018' or 'd00176' or 
'd05265' or 'd00032' or drugid3 = 'd00134' or 'd00004' or 'd03847' or 
'd00709' or 'd00128' or 'd00018' or 'd00176' or 'd05265' or 'd00032' or 
drugid4 = 'd00134' or 'd00004' or 'd03847' or 'd00709' or 'd00128' or 
'd00018' or 'd00176' or 'd05265' or 'd00032' or drugid5 = 'd00134' or 
'd00004' or 'd03847' or 'd00709' or 'd00128' or 'd00018' or 'd00176' or 
'd05265' or 'd00032' or drugid6 = 'd00134' or 'd00004' or 'd03847' or 
'd00709' or 'd00128' or 'd00018' or 'd00176' or 'd05265' or 'd00032' or 
drugid7 = 'd00134' or 'd00004' or 'd03847' or 'd00709' or 'd00128' or 
'd00018' or 'd00176' or 'd05265' or 'd00032' or drugid8 = 'd00134' or 
'd00004' or 'd03847' or 'd00709' or 'd00128' or 'd00018' or 'd00176' or 
'd05265' or 'd00032' then betablocker= 1; 
 
if vdayr = 1 or vdayr = 7 then day = 0; 
if vdayr >=2 & vdayr <7 then day = 1; 
 
/*change in arrtime unknown coding for 2009*/ 
if arrtime >=0000 then hours= 0; 
if arrtime >=0800 then hours = 1; 
if arrtime >=2201 then hours = 0; 
if arrtime = (-9) then hours =.; 
 
/*change in rfv unknown coding for 2009*/ 
chestpain = 0; 
if (rfv1 >=89900 & rfv1 <=90000) or (rfv2 >=89900 & rfv2 <=90000) or (rfv3 
>=89900 & rfv3 <=90000) or rfv1 = (-9) or rfv2 = (-9) or rfv3 = (-9) then 
chestpain =.; 
if rfv1 = 10501 or rfv2 = 10501 or rfv3 = 10501 then chestpain = 1; 
 
/*change in residnce coding for 2009*/ 
if residnce = 2 then ptresidnce = 1; 
if residnce = 1 or (residnce >=3 & residnce <=5) then ptresidnce = 0; 
if residnce = (-8) or residnce = (-9) then ptresidnce = .; 
 
/*change in ptrace coding for 2009*/ 
if racer = 1 then ptrace = 1; 
if racer = 2 then ptrace = 2; 
if racer = 3 then ptrace = 0; 
 
/*change in paytype unknown coding for 2009*/ 
if paytyper = 1 then payment = 1; 
if paytyper = 2 then payment = 2; 
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if paytyper = 3 then payment = 3; 
if paytyper >=4 & paytyper <=7 then payment = 0; 
if paytyper = (-8) or paytyper = (-9) then payment = .; 
/*change arrival coding in 2009*/ 
if arrems = 1 then arrival = 1; 
if arrems = 2 then arrival = 0; 
if arrems = (-8) or arrems = (-9) then arrival = .; 
 
/*change in admission coding in 2009*/ 
if admit = 1 then admission = 1; 
if admit = 2 or admit = 3 or admit = 4 then admission = 2; 
if admit = 5 or admit = 6 then admission = 0; 
if admit = (-7) or admit = (-8) or admit = (-9) then admission = .; 
 
/*change in triage coding for 2009*/ 
if immedr = 1 or immedr = 2 or immedr = 3 then triage = 1; 
if immedr = 4 or immedr = 5 then triage = 2; 
if immedr = 7 then triage = .; 
 
if dieded = 1 then deathed = 1; 
if dieded = 0 then deathed = 0; 
 
if tranoth = 1 then transferhospital = 1; 
if tranoth = 0 then transferhospital = 0; 
 
if ethun = 1 then ethnicity = 1; 
if ethun = 2 then ethnicity = 2; 
if ethun = (-9) then ethnicity = .; 
 
if pulse =<60 then bradycardia = 1; 
else bradycardia = 0; 
 
if bpsys =<90 then hypotension = 1; 
else hypotension = 0; 
 
if bradycardia = 1 or hypotension = 1 then Contraindication = 1; 
else Contraindication = 0; 
 
if attphys = 0 then physcian = 0; 
if attphys = 1 then physcian = 1; 
 
if rnlpn = 0 then nurse = 0; 
if rnlpn = 1 then nurse = 1; 
 
if msa = 1 then metro = 1; 
if msa = 2 then metro = 2; 
 
if owner = 1 then ownership = 1; 
if owner = 2 then ownership = 2; 
if owner = 3 then ownership = 3; 
 
if arrtime >=0800 & arrtime =< 1559 then time= 1; 
if arrtime >=1600 & arrtime =< 2359 then time = 2; 
if arrtime >=0000 & arrtime =< 0759 then time = 3; 
if arrtime = (-9) then time = .; 
 
options nofmterr; 
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run;  
 
/*check the keep list for every year*/ 
data nhamcs.nhamcs10small; 
set nhamcs.nhamcs10work; 
keep betablocker aspirin antiplatelet drugid1 drugid2 drugid3 drugid4 drugid5 
drugid6 drugid7 drugid8 seen AMIdisch older participant participant1 
participant2 participant3 agecat chestpain day time ptresidnce ptrace arrival 
admission payment triage waittime physcian resint nursepr nurse physasst 
deathed transferhospital ethnicity age sex pulse bradycardia bpsys 
hypotension contraindication disch7da cardenz cardmon ekg totdiag totproc los 
hdstat patwt region metro ownership hospcode patcode cstratm cpsum year edwt 
ereminde;  
run; 
SAS code for the analysis program 
/*Analysis program for Maryam Alowayesh Dissertation, last modified April 8th 
2013*/ 
 
/*Demographic Descriptives*/ 
 
/*Descriptive age*/ 
proc surveymeans data=nhamcs.nhamcs10ed_opdappend_end; 
var age; 
domain participant; 
cluster cpsum; 
strata cstratm; 
weight patwt; 
title 'descriptive age';  
options nofmterr; 
run; 
 
/*Descriptive demographic: sex race ethnicity payment residence*/ 
proc surveyfreq data=nhamcs.nhamcs10ed_opdappend_end; 
tables participant*sex participant*ptrace participant*ethnicity 
participant*payment participant*ptresidnce/ row CL CLWT; 
cluster cpsum; 
strata cstratm; 
weight patwt; 
title 'descriptive demographics';  
options nofmterr; 
run; 
 
/*Clinical Descriptives: totproc totdiag*/ 
proc surveymeans data=nhamcs.nhamcs10ed_opdappend_end; 
domain participant; 
var totdiag totproc; 
cluster cpsum; 
strata cstratm; 
weight patwt; 
title 'totdiag totproc Descriptives';  
options nofmterr; 
run; 
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/*Clinical Descriptives: chestpain triage hypotension bradycardia cardenz 
cardmon ekg*/ 
proc surveyfreq data=nhamcs.nhamcs10ed_opdappend_end; 
tables participant*chestpain participant*triage participant*hypotension 
participant*bradycardia participant*cardenz participant*cardmon 
participant*ekg  /row CL CLWT ; 
cluster cpsum; 
strata cstratm; 
weight patwt; 
title 'clinical descriptive';  
options nofmterr; 
run; 
 
/*Visit Descriptives: arrival day time disch7da hdstat physcian resint 
nursepr nurse physasst*/ 
proc surveyfreq data=nhamcs.nhamcs10ed_opdappend_end; 
tables participant*arrival participant*day participant*disch7da 
participant*hdstat participant*physcian participant*resint 
participant*nursepr participant*nurse participant*physasst/row CL CLWT; 
cluster cpsum; 
strata cstratm; 
weight patwt; 
title 'visit Descriptives';  
options nofmterr; 
run; 
 
/*Hospital Descriptives: region metro ownership ereminde*/ 
proc surveyfreq data=nhamcs.nhamcs10ed_opdappend_end; 
tables participant*region participant*metro participant*ownership 
participant*ereminde/row CL CLWT; 
cluster cpsum; 
strata cstratm; 
weight patwt; 
title 'hospital Descriptives';  
options nofmterr; 
run; 
 
/*AIM 1: trend of aspirin_antiplatelet across years*/ 
proc surveylogistic data=nhamcs.nhamcs10ed_opdappend_end; 
model aspirin_antiplatelet (event ='1')= year; 
domain participant; 
cluster cpsum; 
strata cstratm; 
weight patwt; 
title 'trend of aspirin_antiplatelet';  
options nofmterr; 
run; 
 
/*AIM 1: trend of betablocker across years*/ 
proc surveylogistic data=nhamcs.nhamcs10ed_opdappend_end; 
model betablocker (event ='1')= year; 
domain participant; 
cluster cpsum; 
strata cstratm; 
weight patwt; 
title 'trend of betablocker';  
options nofmterr; 
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run; 
 
 
/*Associations with Demographic Characteristics*/ 
 
/*AIM 2: age (older_65) and aspirin_antiplatelet (new_participant)*/ 
proc surveylogistic data=nhamcs.nhamcs10ed_opdappend_end; 
class older_65 sex ptrace; 
model aspirin_antiplatelet (event ='1')= older_65 sex ptrace; 
domain new_participant; 
cluster cpsum; 
strata cstratm; 
weight patwt; 
title 'older_65 and new_participant and aspirin_antiplatelet';  
options nofmterr; 
run; 
 
/*AIM 2: age (older_65) and betablocker (new_participant)*/ 
proc surveylogistic data=nhamcs.nhamcs10ed_opdappend_end; 
class older_65; 
model betablocker (event ='1')= older_65; 
domain new_participant; 
cluster cpsum; 
strata cstratm; 
weight patwt; 
title 'older_65 and new_participant and betablocker';  
options nofmterr; 
run; 
 
/*AIM 2: sex and aspirin_antiplatelet*/ 
proc surveylogistic data=nhamcs.nhamcs10ed_opdappend_end; 
class sex; 
model aspirin_antiplatelet (event ='1')= sex; 
domain participant; 
cluster cpsum; 
strata cstratm; 
weight patwt; 
title 'sex+ aspirin_antiplatelet';  
options nofmterr; 
run; 
 
/*AIM 2: sex and betablocker*/ 
proc surveylogistic data=nhamcs.nhamcs10ed_opdappend_end; 
class sex ptrace; 
model betablocker (event ='1')= sex ptrace age; 
domain participant; 
cluster cpsum; 
strata cstratm; 
weight patwt; 
title 'sex+ betablocker';  
options nofmterr; 
run; 
 
/*AIM 2: race and aspirin_antiplatelet*/ 
proc surveylogistic data=nhamcs.nhamcs10ed_opdappend_end; 
class ptrace; 
model aspirin_antiplatelet (event ='1')= ptrace; 
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domain participant; 
cluster cpsum; 
strata cstratm; 
weight patwt; 
title 'ptrace+ aspirin_antiplatelet';  
options nofmterr; 
run; 
 
/*AIM 2: race and betablocker*/ 
proc surveylogistic data=nhamcs.nhamcs10ed_opdappend_end; 
class ptrace; 
model betablocker (event ='1')= ptrace; 
domain participant; 
cluster cpsum; 
strata cstratm; 
weight patwt; 
title 'ptrace+ betablocker';  
options nofmterr; 
run; 
 
/*AIM 2: ethnicity and aspirin_antiplatelet*/ 
proc surveylogistic data=nhamcs.nhamcs10ed_opdappend_end; 
class ethnicity; 
model aspirin_antiplatelet (event ='1')= ethnicity; 
domain participant; 
cluster cpsum; 
strata cstratm; 
weight patwt; 
title 'ethnicity+ aspirin_antiplatelet';  
options nofmterr; 
run; 
 
/*AIM 2: ethnicity and betablocker*/ 
proc surveylogistic data=nhamcs.nhamcs10ed_opdappend_end; 
class ethnicity; 
model betablocker (event ='1')= ethnicity; 
domain participant; 
cluster cpsum; 
strata cstratm; 
weight patwt; 
title 'ethnicity+ betablocker';  
options nofmterr; 
run; 
 
/*AIM 2: payment and aspirin_antiplatelet*/ 
proc surveylogistic data=nhamcs.nhamcs10ed_opdappend_end; 
class payment; 
model aspirin_antiplatelet (event ='1')= payment; 
domain participant; 
cluster cpsum; 
strata cstratm; 
weight patwt; 
title 'sex+ aspirin_antiplatelet';  
options nofmterr; 
run; 
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/*AIM 2: payment and betablocker*/ 
proc surveylogistic data=nhamcs.nhamcs10ed_opdappend_end; 
class payment; 
model betablocker (event ='1')= payment; 
domain participant; 
cluster cpsum; 
strata cstratm; 
weight patwt; 
title 'payment+ betablocker';  
options nofmterr; 
run; 
 
/*AIM 2: residnce and aspirin_antiplatelet*/ 
proc surveylogistic data=nhamcs.nhamcs10ed_opdappend_end; 
class ptresidnce sex ptrace; 
model aspirin_antiplatelet (event ='1')= ptresidnce sex ptrace age; 
domain participant; 
cluster cpsum; 
strata cstratm; 
weight patwt; 
title 'ptresidnce+ aspirin_antiplatelet';  
options nofmterr; 
run; 
 
/*AIM 2: residnce and betablocker*/ 
proc surveylogistic data=nhamcs.nhamcs10ed_opdappend_end; 
class ptresidnce; 
model betablocker (event ='1')= ptresidnce; 
domain participant; 
cluster cpsum; 
strata cstratm; 
weight patwt; 
title 'ptresidnce+ betablocker';  
options nofmterr; 
run; 
 
/*Association with Clinical Characteristics*/ 
 
/*AIM 2: chestpain and aspirin_antiplatelet*/ 
proc surveylogistic data=nhamcs.nhamcs10ed_opdappend_end; 
class chestpain; 
model aspirin_antiplatelet (event ='1')= chestpain; 
domain participant; 
cluster cpsum; 
strata cstratm; 
weight patwt; 
title 'chestpain+ aspirin_antiplatelet';  
options nofmterr; 
run; 
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/*AIM 2: chestpain and betablocker*/ 
proc surveylogistic data=nhamcs.nhamcs10ed_opdappend_end; 
class chestpain ptrace sex; 
model betablocker (event ='1')= chestpain age ptrace sex; 
domain participant; 
cluster cpsum; 
strata cstratm; 
weight patwt; 
title 'chestpain+ betablocker';  
options nofmterr; 
run; 
 
/*AIM 2: triage and aspirin_antiplatelet*/ 
proc surveylogistic data=nhamcs.nhamcs10ed_opdappend_end; 
class triage sex ptrace; 
model aspirin_antiplatelet (event ='1')= triage age sex ptrace; 
domain participant; 
cluster cpsum; 
strata cstratm; 
weight patwt; 
title 'triage+ aspirin_antiplatelet';  
options nofmterr; 
run; 
 
/*AIM 2: triage and betablocker*/ 
proc surveylogistic data=nhamcs.nhamcs10ed_opdappend_end; 
class triage; 
model betablocker (event ='1')= triage; 
domain participant; 
cluster cpsum; 
strata cstratm; 
weight patwt; 
title 'triage+ betablocker';  
options nofmterr; 
run; 
 
/*AIM 2: totproc and aspirin_antiplatelet*/ 
proc surveylogistic data=nhamcs.nhamcs10ed_opdappend_end; 
model aspirin_antiplatelet (event ='1')= totproc; 
domain participant; 
cluster cpsum; 
strata cstratm; 
weight patwt; 
title 'totproc+ aspirin_antiplatelet';  
options nofmterr; 
run; 
 
/*AIM 2: totproc and betablocker*/ 
proc surveylogistic data=nhamcs.nhamcs10ed_opdappend_end; 
model betablocker (event ='1')= totproc; 
domain participant; 
cluster cpsum; 
strata cstratm; 
weight patwt; 
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title 'totproc+ betablocker';  
options nofmterr; 
run; 
/*AIM 2: totdiag and aspirin_antiplatelet*/ 
proc surveylogistic data=nhamcs.nhamcs10ed_opdappend_end; 
class ptrace sex; 
model aspirin_antiplatelet (event ='1')= totdiag sex age ptrace; 
domain participant; 
cluster cpsum; 
strata cstratm; 
weight patwt; 
title 'totdiag+ aspirin_antiplatelet';  
options nofmterr; 
run; 
 
/*AIM 2: totdiag and betablocker*/ 
proc surveylogistic data=nhamcs.nhamcs10ed_opdappend_end; 
class sex ptrace; 
model betablocker (event ='1')= totdiag sex ptrace age; 
domain participant; 
cluster cpsum; 
strata cstratm; 
weight patwt; 
title 'totdiag+ betablocker';  
options nofmterr; 
run; 
 
/*Association with Visit Characteristics*/ 
 
/*AIM 2: time and aspirin_antiplatelet*/ 
proc surveylogistic data=nhamcs.nhamcs10ed_opdappend_endingf; 
class time; 
model aspirin_antiplatelet (event ='1')= time; 
domain participant; 
cluster cpsum; 
strata cstratm; 
weight patwt; 
title 'time+ aspirin_antiplatelet';  
options nofmterr; 
run; 
 
/*AIM 2: hours and betablocker*/ 
proc surveylogistic data=nhamcs.nhamcs10ed_opdappend_endingf; 
class time; 
model betablocker (event ='1')= time; 
domain participant; 
cluster cpsum; 
strata cstratm; 
weight patwt; 
title 'time+ betablocker';  
options nofmterr; 
run; 
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/*AIM 2: day and aspirin_antiplatelet*/ 
proc surveylogistic data=nhamcs.nhamcs10ed_opdappend_end; 
class day; 
model aspirin_antiplatelet (event ='1')= day; 
domain participant; 
cluster cpsum; 
strata cstratm; 
weight patwt; 
title 'day+ aspirin_antiplatelet';  
options nofmterr; 
run; 
 
/*AIM 2: day and betablocker*/ 
proc surveylogistic data=nhamcs.nhamcs10ed_opdappend_end; 
class day; 
model betablocker (event ='1')= day; 
domain participant; 
cluster cpsum; 
strata cstratm; 
weight patwt; 
title 'day+ betablocker';  
options nofmterr; 
run; 
 
/*AIM 2: arrival and aspirin_antiplatelet*/ 
proc surveylogistic data=nhamcs.nhamcs10ed_opdappend_end; 
class arrival sex ptrace; 
model aspirin_antiplatelet (event ='1')= arrival sex ptrace age; 
domain participant; 
cluster cpsum; 
strata cstratm; 
weight patwt; 
title 'arrival+ aspirin_antiplatelet';  
options nofmterr; 
run; 
 
/*AIM 2: arrival and betablocker*/ 
proc surveylogistic data=nhamcs.nhamcs10ed_opdappend_end; 
class arrival; 
model betablocker (event ='1')= arrival; 
domain participant; 
cluster cpsum; 
strata cstratm; 
weight patwt; 
title 'arrival+ betablocker';  
options nofmterr; 
run; 
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/*AIM 2: physcian and aspirin_antiplatelet*/ 
proc surveylogistic data=nhamcs.nhamcs10ed_opdappend_end; 
class physcian; 
model aspirin_antiplatelet (event ='1')= physcian; 
domain participant; 
cluster cpsum; 
strata cstratm; 
weight patwt; 
title 'physcian+ aspirin_antiplatelet';  
options nofmterr; 
run; 
 
/*AIM 2: physcian and betablocker*/ 
proc surveylogistic data=nhamcs.nhamcs10ed_opdappend_end; 
class physcian; 
model betablocker (event ='1')= physcian; 
domain participant; 
cluster cpsum; 
strata cstratm; 
weight patwt; 
title 'physcian+ betablocker';  
options nofmterr; 
run; 
 
/*AIM 2: resint and aspirin_antiplatelet*/ 
proc surveylogistic data=nhamcs.nhamcs10ed_opdappend_end; 
class resint; 
model aspirin_antiplatelet (event ='1')= resint; 
domain participant; 
cluster cpsum; 
strata cstratm; 
weight patwt; 
title 'resint+ aspirin_antiplatelet';  
options nofmterr; 
run; 
 
/*AIM 2: resint and betablocker*/ 
proc surveylogistic data=nhamcs.nhamcs10ed_opdappend_end; 
class resint; 
model betablocker (event ='1')= resint; 
domain participant; 
cluster cpsum; 
strata cstratm; 
weight patwt; 
title 'resint+ betablocker';  
options nofmterr; 
run; 
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/*AIM 2: nurse and aspirin_antiplatelet*/ 
proc surveylogistic data=nhamcs.nhamcs10ed_opdappend_end; 
class nurse; 
model aspirin_antiplatelet (event ='1')= nurse; 
domain participant; 
cluster cpsum; 
strata cstratm; 
weight patwt; 
title 'nurse+ aspirin_antiplatelet';  
options nofmterr; 
run; 
 
/*AIM 2: nurse and betablocker*/ 
proc surveylogistic data=nhamcs.nhamcs10ed_opdappend_end; 
class nurse; 
model betablocker (event ='1')= nurse; 
domain participant; 
cluster cpsum; 
strata cstratm; 
weight patwt; 
title 'nurse+ betablocker';  
options nofmterr; 
run; 
 
/*AIM 2: nursepr and aspirin_antiplatelet*/ 
proc surveylogistic data=nhamcs.nhamcs10ed_opdappend_end; 
class nursepr ptrace sex; 
model aspirin_antiplatelet (event ='1')= nursepr ptrace sex age; 
domain participant; 
cluster cpsum; 
strata cstratm; 
weight patwt; 
title 'nursepr+ aspirin_antiplatelet';  
options nofmterr; 
run; 
 
/*AIM 2: nursepr and betablocker*/ 
proc surveylogistic data=nhamcs.nhamcs10ed_opdappend_end; 
class nursepr; 
model betablocker (event ='1')= nursepr; 
domain participant; 
cluster cpsum; 
strata cstratm; 
weight patwt; 
title 'nursepr+ betablocker';  
options nofmterr; 
run; 
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/*AIM 2: physasst and aspirin_antiplatelet*/ 
proc surveylogistic data=nhamcs.nhamcs10ed_opdappend_end; 
class physasst; 
model aspirin_antiplatelet (event ='1')= physasst; 
domain participant; 
cluster cpsum; 
strata cstratm; 
weight patwt; 
title 'physasst+ aspirin_antiplatelet';  
options nofmterr; 
run; 
 
/*AIM 2: physasst and betablocker*/ 
proc surveylogistic data=nhamcs.nhamcs10ed_opdappend_end; 
class physasst; 
model betablocker (event ='1')= physasst; 
domain participant; 
cluster cpsum; 
strata cstratm; 
weight patwt; 
title 'physasst+ betablocker';  
options nofmterr; 
run; 
 
/*Association with Hospital Characteristics*/ 
 
/*AIM 2: region and aspirin_antiplatelet*/ 
proc surveylogistic data=nhamcs.nhamcs10ed_opdappend_end; 
class region; 
model aspirin_antiplatelet (event ='1')= region; 
domain participant; 
cluster cpsum; 
strata cstratm; 
weight patwt; 
title 'region+ aspirin_antiplatelet';  
options nofmterr; 
run; 
 
/*AIM 2: region and betablocker*/ 
proc surveylogistic data=nhamcs.nhamcs10ed_opdappend_end; 
class region; 
model betablocker (event ='1')= region; 
domain participant; 
cluster cpsum; 
strata cstratm; 
weight patwt; 
title 'region+ betablocker';  
options nofmterr; 
run; 
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/*AIM 2: Metro and aspirin_antiplatelet*/ 
proc surveylogistic data=nhamcs.nhamcs10ed_opdappend_end; 
class metro sex ptrace; 
model aspirin_antiplatelet (event ='1')= metro sex ptrace age; 
domain participant; 
cluster cpsum; 
strata cstratm; 
weight patwt; 
title 'metro+ aspirin_antiplatelet';  
options nofmterr; 
run; 
 
/*AIM 2: metro and betablocker*/ 
proc surveylogistic data=nhamcs.nhamcs10ed_opdappend_end; 
class metro; 
model betablocker (event ='1')= metro; 
domain participant; 
cluster cpsum; 
strata cstratm; 
weight patwt; 
title 'metro+ betablocker';  
options nofmterr; 
run; 
 
/*AIM 2: ownership and aspirin_antiplatelet*/ 
proc surveylogistic data=nhamcs.nhamcs10ed_opdappend_end; 
class ownership; 
model aspirin_antiplatelet (event ='1')= ownership; 
domain participant; 
cluster cpsum; 
strata cstratm; 
weight patwt; 
title 'ownership+ aspirin_antiplatelet';  
options nofmterr; 
run; 
 
/*AIM 2: ownership and betablocker*/ 
proc surveylogistic data=nhamcs.nhamcs10ed_opdappend_end; 
class ownership; 
model betablocker (event ='1')= ownership; 
domain participant; 
cluster cpsum; 
strata cstratm; 
weight patwt; 
title 'ownership+ betablocker';  
options nofmterr; 
run; 
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/*AIM 3: los and aspirin_antiplatelet (participant_los)*/ 
proc surveymeans data=nhamcs.nhamcs10ed_opdappend_end; 
var los; 
domain participant; 
cluster cpsum; 
strata cstratm; 
weight patwt; 
title 'descriptive los';  
options nofmterr; 
run; 
 
proc surveyreg data=nhamcs.nhamcs10ed_opdappend_end; 
model los = aspirin_antiplatelet / CLPARM;  
domain participant_los; 
cluster cpsum; 
strata cstratm; 
weight patwt; 
title 'los+aspirin_antiplatelet';  
options nofmterr; 
run; 
 
/*AIM 3: los and betablocker (participant_los)*/ 
proc surveyreg data=nhamcs.nhamcs10ed_opdappend_end; 
model los = betablocker / CLPARM;  
domain participant_los; 
cluster cpsum; 
strata cstratm; 
weight patwt; 
title 'los+betablocker';  
options nofmterr; 
run; 
 
/*AIM 3: aspirin_antiplatelet and betablocker mortality*/ 
proc surveyfreq data=nhamcs.nhamcs10ed_opdappend_end; 
tables participant*aspirin_antiplatelet*hdstat participant*betablocker*hdstat 
/ chisq row CL CLWT; 
cluster cpsum; 
strata cstratm; 
weight patwt; 
title 'hdstat*chisquare';  
options nofmterr; 
run; 
 
/*AIM 4: descriptive ereminde*/ 
proc surveyfreq data=nhamcs.nhamcs10ed_opdappend_endingf; 
tables participant*ereminde / row CL CLWT; 
cluster cpsum; 
strata cstratm; 
weight patwt; 
title 'descriptive ereminde';  
options nofmterr; 
run; 
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/*AIM 4: antiplatelet and ereminde*/ 
proc surveylogistic data=nhamcs.nhamcs10ed_opdappend_end; 
class ereminde; 
model aspirin_antiplatelet (event ='1')= ereminde; 
domain participant; 
cluster cpsum; 
strata cstratm; 
weight patwt; 
title 'antiplatelet+ereminde ';  
options nofmterr; 
run; 
 
/*AIM 4: betablocker and ereminde*/ 
proc surveylogistic data=nhamcs.nhamcs10ed_opdappend_end; 
class ereminde; 
model betablocker (event='1') = ereminde; 
domain participant; 
cluster cpsum; 
strata cstratm; 
weight patwt; 
title 'ereminde+betablocker';  
options nofmterr; 
run; 
 
/*Descriptive contraindication*/ 
proc surveyfreq data=nhamcs.nhamcs10ed_opdappend_end; 
tables participant*contraindication / row CL CLWT; 
cluster cpsum; 
strata cstratm; 
weight patwt; 
title 'descriptive contraindication';  
options nofmterr; 
run; 
 
/*Descriptive betablockers*/ 
proc surveyfreq data=nhamcs.nhamcs10ed_opdappend_end; 
tables participant*betablocker / row CL CLWT; 
cluster cpsum; 
strata cstratm; 
weight patwt; 
title 'descriptive betablockers';  
options nofmterr; 
run; 
 
/*chestpain and age*/ 
proc surveyfreq data=nhamcs.nhamcs10ed_opdappend_end; 
tables participant*agecat*chestpain / chisq row CL CLWT; 
cluster cpsum; 
strata cstratm; 
weight patwt; 
title 'descriptive chestpain';  
options nofmterr; 
run; 
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/*sex and age*/ 
proc surveyfreq data=nhamcs.nhamcs10ed_opdappend_end; 
tables participant*agecat*sex / chisq row CL CLWT; 
cluster cpsum; 
strata cstratm; 
weight patwt; 
title 'descriptive sex*age';  
options nofmterr; 
run; 
 
/*hdstat and age*/ 
proc surveyfreq data=nhamcs.nhamcs10ed_opdappend_end; 
tables participant*agecat*hdstat / chisq row CL CLWT; 
cluster cpsum; 
strata cstratm; 
weight patwt; 
title 'hdstat*age';  
options nofmterr; 
run; 
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